

Prof. SEMRA PAYDAŞ

Personal Information

Office Phone: [+90 322 338 6060](tel:+903223386060) Extension: 3142

Email: sepay@cu.edu.tr

Web: <https://avesis.cu.edu.tr//sepay>

Address: Çukurova Üniversitesi Tıp Fakültesi Balcalı hastanesi Onkoloji BD polikliniği 01330 ADANA

International Researcher IDs

ORCID: 0000-0003-4642-3693

Publons / Web Of Science ResearcherID: F-3132-2018

Yoksis Researcher ID: 3936

Education Information

Expertise In Medicine, Cukurova University, Tıp Fakültesi, Dahiliye, Turkey 1981 - 1986

Undergraduate, Cukurova University, Tıp Fakültesi, Turkey 1978 - 1981

Foreign Languages

English, B2 Upper Intermediate

Dissertations

Expertise In Medicine, TETANOZDA KLİNİK BULGULAR VE KORTKOSTEROİDİN TEDAVİDEKİ YERİ , Cukurova University, Tıp Fakültesi, Dahiliye, 1986

Research Areas

Medicine, Health Sciences, Internal Medicine Sciences, Internal Diseases , Hematology, Oncology

Academic Titles / Tasks

Professor, Cukurova University, Çukurova Üniversitesi Tıp Fakültesi, Dahili Tıp Bilimleri, 1981 - Continues

Published journal articles indexed by SCI, SSCI, and AHCI

- I. Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG)**
YAŞAR H. A., Aktas B. Y., Ucar G., SEZGİN GÖKSU S., Bilgetekin I., Cakar B., Sakin A., Ates O., Basoglu T., Arslan C., et al.
Clinical Genitourinary Cancer, vol.22, no.3, 2024 (SCI-Expanded)
- II. A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy**

Kilickap S., Ozturk A., Karadurmus N., KORKMAZ T., Yumuk P. F., ÇİÇİN İ., PAYDAŞ S., Cilbir E., Sakalar T., Uysal M., et al.

Medicine (United States), vol.103, no.21, 2024 (SCI-Expanded)

- III. **Association of systemic inflammatory markers with prognosis in erlotinib-treated EGFR-mutant non-small cell lung cancer**
Yetişir A. E., PAYDAŞ S., Büyüksimşek M., Oğul A., Kolsuz İ., Kızı M. M.
Journal of Cancer Research and Therapeutics, vol.20, no.1, pp.285-288, 2024 (SCI-Expanded)
- IV. **A new scoring system to predict survival in elderly advanced stage Hodgkin lymphoma patients**
MEHTAP Ö., TOPTAŞ T., Dal M. S., Karadag F. K., Atas U., ÖZSAN G. H., SAYINALP N., Saydam G., Uçar M. A., Kırkızlar H. O., et al.
Leukemia and Lymphoma, 2024 (SCI-Expanded)
- V. **Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study**
BAŞOĞLU TÜYLÜ T., Sakin A., Erol C., Ozden E., ÇABUK D., Cilbir E., Tataroglu ozyukseler D., Ayhan M., Sendur M. A., Dogan M., et al.
JOURNAL OF CHEMOTHERAPY, vol.35, no.2, pp.142-149, 2023 (SCI-Expanded)
- VI. **Analysis of breast cancer classification robustness with radiomics feature extraction and deep learning techniques**
Rashid H. U., İBRİKÇİ T., PAYDAŞ S., BİNOKAY F., ÇEVİK U.
EXPERT SYSTEMS, vol.39, no.8, 2022 (SCI-Expanded)
- VII. **The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study**
Ozdemir O., Zengel B., Yildiz Y., Uluc B. O., ÇABUK D., Ozden E., Salim D. K., PAYDAŞ S., Demir A., Diker O., et al.
ANTI-CANCER DRUGS, vol.33, no.7, pp.663-670, 2022 (SCI-Expanded)
- VIII. **The effect of Paraoxonase gene polymorphisms and paraoxonase enzyme activity on Non-Hodgkin lymphoma**
ÇINAR E., Akgollu E., YÜCEBİLGİÇ G., BİLGİN R., PAYDAŞ S.
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, vol.41, no.5-6, pp.489-502, 2022 (SCI-Expanded)
- IX. **GC-MS based metabolite fingerprinting of serous ovarian carcinoma and benign ovarian tumor**
Eroglu E. C., KÜÇÜKGÖZ GÜLEÇ Ü., VARDAR M. A., PAYDAŞ S.
EUROPEAN JOURNAL OF MASS SPECTROMETRY, vol.28, pp.12-24, 2022 (SCI-Expanded)
- X. **Castleman Disease: A Multicenter Case Series from Turkey**
GÜNDÜZ E., KIRKIZLAR H. O., Umit E. G., KARAMAN GÜLSARAN S., ÖZKOCAMAN V., ÖZKALEMKAŞ F., CANDAR Ö., ELVERDİ T., Kucukyurt S., PAYDAŞ S., et al.
TURKISH JOURNAL OF HEMATOLOGY, vol.39, no.2, pp.130-135, 2022 (SCI-Expanded)
- XI. **Jugular Paraganglioma Presenting with a Tumor Thrombus Extending from Posterior Fossa to Right Atrium and Multiple Skeletal Metastases**
Pehlivan U. A., OKTAY K., ONAN H. B., AÇIKALIN A., Keser C., PAYDAŞ S.
CURRENT MEDICAL IMAGING, vol.18, no.13, pp.1439-1442, 2022 (SCI-Expanded)
- XII. **Easier and more explanatory indices by integrating leukocyte lymphocyte ratio (LLR) and prognostic nutritional index (PNI) to IPS systems in cases with classical Hodgkin lymphoma**
PAYDAŞ S., Lacin S., Dogan M., Barista I., Yildiz B., Seydaoglu G., Karadurmus N., Civriz S., Kaplan M., Yagci M., et al.
LEUKEMIA RESEARCH, vol.107, 2021 (SCI-Expanded)
- XIII. **Severe Lymphocytosis in a Case of Diffuse Large B-Cell Lymphoma Treated by Ibrutinib**
Paydas S., E B., M T., T Ö.
TURKISH JOURNAL OF HAEMATOLOGY, vol.38, no.4, pp.337-338, 2021 (SCI-Expanded)
- XIV. **Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study**
Bilgin B., Sendur M. A. N., Yucel S., Celik E., Ozyukseler D. T., Ayhan M., BAŞOĞLU TÜYLÜ T., Ilhan A., Akdeniz N., Gulmez A., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.147, no.7, pp.2145-2152, 2021 (SCI-Expanded)

- XV. **IPS-3 Validation in 1012 cases with classical hodgkin lymphoma**
PAYDAŞ S., Lacin S., Dogan M., BARIŞTA İ., Yildiz B., SEYDAOĞLU G., Karadurmus N., Civriz S., Kaplan M. A., Yagci M., et al.
LEUKEMIA RESEARCH, vol.102, 2021 (SCI-Expanded)
- XVI. **Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial**
Sezer A., Kılıçkap S., Gümüş M., Bondarenko I., Özgüroğlu M., Gogishvili M., Türk H. M., Çiçin İ., Bentsion D., Gladkov O., et al.
LANCET, vol.397, no.10274, pp.592-604, 2021 (SCI-Expanded)
- XVII. **Sarcoid-like reaction in cases treated by checkpoint inhibitors**
PAYDAŞ S.
MEDICAL ONCOLOGY, vol.38, no.3, 2021 (SCI-Expanded)
- XVIII. **Worse patient-physician relationship is associated with more fear of cancer recurrence (Deimos Study): A study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG)**
Alkan A., Yasar A., Guc Z. G., Gurbuz M., BAŞOĞLU TÜYLÜ T., SEZGİN GÖKSU S., Basal F. B., TÜRK H. M., Ozdemir O., Cinkir H. Y., et al.
EUROPEAN JOURNAL OF CANCER CARE, vol.29, no.6, 2020 (SCI-Expanded)
- XIX. **Demographical and Clinical Features of Marginal Zone Lymphomas: A Retrospective Study of Turkish Oncology Group (TOG)**
Turkkan G., Alkan A., PAYDAŞ S., TANRIVERDİ Ö., Karakas Y., Karadurmus N., Sakin A., Temiz S., Arpacı E., Akin M., et al.
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, vol.36, no.4, pp.640-645, 2020 (SCI-Expanded)
- XX. **Prognosis Trend of Grade 2 Endometrioid Endometrial Carcinoma: Toward Grade 1 or 3?**
KHATİB G., Gulec Ü., GÜZEL A. B., Bagir E., PAYDAŞ S., VARDAR M. A.
PATHOLOGY & ONCOLOGY RESEARCH, vol.26, no.4, pp.2351-2356, 2020 (SCI-Expanded)
- XXI. **GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients**
Peled N., Gillis R., KILIÇKAP S., Froesch P., Orlov S., Filippova E., Demirci U., Christopoulos P., ÇİÇİN İ., Basal F. B., et al.
LUNG CANCER, vol.148, pp.48-54, 2020 (SCI-Expanded)
- XXII. **Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma**
BEKSAÇ M., Aydın Y., GÖKER H., Turgut M., Besisik S. K., Cagırgan S., Tuğlular T., VURAL F., Yagci M., ALACACIOĞLU İ., et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.20, no.8, 2020 (SCI-Expanded)
- XXIII. **Does primary tumor localization has prognostic importance in seminoma patients?: Turkish Oncology Group Study**
Yildiz B., Kucukarda A., Gokyer A., Demiray A. G., PAYDAŞ S., Aral I. P., GÜMÜŞAY Ö., Bilici A., Akdeniz N., Bahceci A., et al.
JOURNAL OF BUON, vol.25, no.2, pp.1130-1135, 2020 (SCI-Expanded)
- XXIV. **Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial**
Demir A., Mandel N. M., PAYDAŞ S., Demir G., ER O., Turhal N. S., Bavbek S., Eralp Y., Saip P. M., Guler E. N., et al.
BALKAN MEDICAL JOURNAL, vol.37, no.2, pp.104-107, 2020 (SCI-Expanded)
- XXV. **Perspective of Turkish Medicine Students on Cancer, Cancer Treatments, Palliative Care, and Oncologists (ARES Study): a Study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG)**
Oktay E., Levent M., Gelincik H., Aktas G., Yumuk F., KORAL L., Arpacı E., Keser M., Alkan A., Karci E., et al.
JOURNAL OF CANCER EDUCATION, vol.35, no.1, pp.69-75, 2020 (SCI-Expanded)
- XXVI. **Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-**

center real-life experience

Ozbalak M., SALİHOĞLU A., Soysal T., Karadogan I., PAYDAŞ S., Ozdemir E., Yildiz B., Karadurmus N., KAYNAR L., Yagci M., et al.

ANNALS OF HEMATOLOGY, vol.99, no.2, pp.301-307, 2020 (SCI-Expanded)

- XXVII. **The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA**
Disel U., Madison R., Abhishek K., Chung J. H., Trabucco S. E., Matos A. O., Frampton G. M., Albacker L. A., Reddy V., Karadurmus N., et al.
ONCOLOGIST, vol.25, no.1, 2020 (SCI-Expanded)
- XXVIII. **Prognostic significance of EGFR, MUC1 and PD-L1 expressions in cases with triple negative breast cancer**
MİRİLİ C., PAYDAŞ S., BAĞIR KILIÇ E., SEYDAOĞLU G., OĞUL A., GÖKÇAY S., BÜYÜKŞİMŞEK M., YETİŞİR A. E., Karaalioglu B., TOHUMCUOĞLU M., et al.
JOURNAL OF BUON, vol.25, no.1, pp.159-167, 2020 (SCI-Expanded)
- XXIX. **Cerebral MRI Mimicking Pachymeningeal Involvement Associated with Intrathecal Treatment**
PAYDAŞ S., Bicakci K.
TURKISH JOURNAL OF HEMATOLOGY, vol.37, no.4, pp.308-309, 2020 (SCI-Expanded)
- XXX. **Prognostic significance of programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression in uterine carcinosarcoma**
Gulec Ü., Bagir E. K., PAYDAŞ S., GÜZEL A. B., GÜMÜRDÜLÜ D., VARDAR M. A.
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, vol.244, pp.51-55, 2020 (SCI-Expanded)
- XXXI. **Efficacy of Prephase Treatment for the Prevention of Tumor Lysis Syndrome in Lymphoma Cases with High Tumor Burden: A Cross-Sectional Study**
Ogul A., PAYDAŞ S., Buyuksimsek M., Yetisir A. E.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.30, no.2, pp.87-93, 2020 (SCI-Expanded)
- XXXII. **Systemic immune-inflammation index predicting survival outcome in patients with classical Hodgkin lymphoma**
Mirili C., PAYDAŞ S., Kapukaya T. K., YILMAZ A.
BIOMARKERS IN MEDICINE, vol.13, no.18, pp.1565-1575, 2019 (SCI-Expanded)
- XXXIII. **Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable \geq Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey**
BEKSAÇ M., Seval G. C., PAYDAŞ S., Tuğlular T. F., ARSLAN Ö., GÖKER H., KAYNAR L., ALTUNTAŞ F., Atalay F., Teke H. U., et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.19, no.10, 2019 (SCI-Expanded)
- XXXIV. **Orbital extramedullary leukaemia is not a rare entity**
PAYDAŞ S.
BRITISH JOURNAL OF HAEMATOLOGY, vol.186, no.3, 2019 (SCI-Expanded)
- XXXV. **Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expressions in type 2 endometrial cancer**
KÜÇÜKGÖZ GÜLEÇ Ü., BAĞIR KILIÇ E., PAYDAŞ S., GÜZEL A. B., GÜMÜRDÜLÜ D., VARDAR M. A.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, vol.300, no.2, pp.377-382, 2019 (SCI-Expanded)
- XXXVI. **Management of adverse effects/toxicity of ibrutinib**
PAYDAŞ S.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol.136, pp.56-63, 2019 (SCI-Expanded)
- XXXVII. **Prognostic significance of neutrophil/lymphocyte ratio (NLR) and correlation with PET-CT metabolic parameters in small cell lung cancer (SCLC)**
Mirili C., Güney İ. B., Paydaş S., Seydaoğlu G., Kapukaya T. K., Oğul A., Gökçay S., Büyüksimşek M., Yetişir A. E., Karaalioglu B., et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, vol.24, no.2, pp.168-178, 2019 (SCI-Expanded)
- XXXVIII. **Tafro syndrome: Critical review for clinicians and pathologists**

- PAYDAŞ S.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol.128, pp.88-95, 2018 (SCI-Expanded)
- XXXIX. **Prognostic value of pre-operative neutrophil/lymphocyte ratio, monocyte count, mean platelet volume, and platelet/lymphocyte ratio in endometrial cancer.**
TEMUR I., Kucukgoz G., Paydas S., GÜZEL A. B., Sucu M., VARDAR M. A.
European journal of obstetrics, gynecology, and reproductive biology, vol.226, pp.25-29, 2018 (SCI-Expanded)
- XL. **PD-1 and PD-L1 expression in thymic epithelial tumours and non-neoplastic thymus.**
Bagir E., Acikalin A., Avci A., Gumurdulu D., Paydas S.
Journal of clinical pathology, vol.71, pp.637-641, 2018 (SCI-Expanded)
- XLI. **EGFR, MUC-1 and PD-L1 expressions in cases with triple negative breast cancer (TNBC).**
Paydas S., Mirili C., Bagir E., Seydaoglu G., Ogul A., Buyuksimsek M., Yetisir A. E., Karaalioglu B., Tohumcuoglu M.
JOURNAL OF CLINICAL ONCOLOGY, vol.36, no.15, 2018 (SCI-Expanded)
- XLII. **Merkel cell carcinoma in Turkey: A multicentric study.**
Yildiz F., Buyuksimsek M., Sakalar T., Aydin O., Turna H., Babacan N. A., Yildiz B., Arslan C., Ozdemir N., Urun Y., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.36, no.15, 2018 (SCI-Expanded)
- XLIII. **Effectiveness of platinum-based treatment for triple negative metastatic breast cancer: A meta-analysis**
KAYA V., Yildirim M., YAZICI G., Gunduz S., BOZCUK H., Paydas S.
Asian Pacific Journal of Cancer Prevention, vol.19, no.5, pp.1169-1173, 2018 (SCI-Expanded)
- XLIV. **PROGRAMMED DEATH-1 (PD-1), PROGRAMMED DEATH-LIGAND 1 (PD-L1) EXPRESSION IN UTERINE GRADE 3 ENDOMETRIOID ADENOCANCER**
Gulec U. K., Bagir E., PAYDAŞ S., GÜZEL A. B., KHATİB G., SEYDAOĞLU G., VARDAR M. A.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, vol.27, pp.1126, 2017 (SCI-Expanded)
- XLV. **Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience**
Bekoz H., Karadurmus N., PAYDAŞ S., TÜRKER A., TOPTAŞ T., Tuglular T. F., SÖNMEZ M., Gulbas Z., Tekgunduz E., Kaya A. H., et al.
ANNALS OF ONCOLOGY, vol.28, no.10, pp.2496-2502, 2017 (SCI-Expanded)
- XLVI. **Coexistence of hypertrophic osteoarthropathy and myelofibrosis**
KELLE B., YILDIZ F., PAYDAŞ S., Bagir E. K., ERGİN M., KOZANOĞLU E.
REVISTA BRASILEIRA DE REUMATOLOGIA, vol.57, no.5, pp.472-474, 2017 (SCI-Expanded)
- XLVII. **Prevalence of cytogenetic abnormalities in chronic lymphocytic leukemia in the southern part of Turkey.**
Bagir E., Acikalin A., Alsancak P., Paydas S., Gurkan E., Ergin M.
Indian journal of cancer, vol.54, pp.572-575, 2017 (SCI-Expanded)
- XLVIII. **Primary central nervous system lymphoma: essential points in diagnosis and management**
PAYDAŞ S.
MEDICAL ONCOLOGY, vol.34, no.4, 2017 (SCI-Expanded)
- XLIX. **Evaluation of lipid profiles in patients treated with capecitabine**
SÜRME LİOĞLU N., PAYDAŞ S., KARATAŞ Y., SEYDAOĞLU G.
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.47, no.4, pp.1206-1209, 2017 (SCI-Expanded)
- L. **Attitudes of cancer patients after diagnosis: How cancer affects social life? A Turkish Oncology Group study**
Nayir E., Koyuncu M. B., Esin E., Turker I., TANRIVERDİ Ö., UYSAL M., Er O., Demir A., Akman T. T., Pilanci K. N., et al.
JOURNAL OF BUON, vol.22, no.1, pp.208-213, 2017 (SCI-Expanded)
- LI. **Clinicopathological features and prognostic factors of ovarian sex-cord stromal tumors**
KOCAKI B., Gulec U. K., KHATİB G., GÜZEL A. B., GÜMÜRDÜLÜ D., PAYDAŞ S., VARDAR M. A.
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, vol.38, no.5, pp.769-774, 2017 (SCI-Expanded)
- LII. **Clinical and pathological results of denosumab treatment for giant cell tumors of bone: Prospective study of 14 cases**
DEVECİ M. A., PAYDAŞ S., GÖNLÜŞEN G., ÖZKAN C., BİÇER Ö. S., TEKİN M.
ACTA ORTHOPAEDICA ET TRAUMATOLOGICA TURCICA, vol.51, no.1, pp.1-6, 2017 (SCI-Expanded)

- LIII. **MORPHOLOGIC EVALUATION OF THE EFFECT OF DENOSUMAB ON GIANT CELL TUMORS OF BONE AND A NEW GRADING SCHEME**
ERDOĞAN K. E., DEVECİ M. A., PAYDAŞ S., GÖNLÜŞEN G.
POLISH JOURNAL OF PATHOLOGY, vol.67, no.4, pp.392-397, 2016 (SCI-Expanded)
- LIV. **Does Preoperative Neutrophil To Lymphocyte Or Platelet To Lymphocyte Ratios Have A Role In Predicting Borderline Ovarian Tumors?**
Khatib G., VARDAR M. A., GÜZEL A. B., Kucukgozgulec U., GÜMÜRDÜLÜ D., PAYDAŞ S.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, vol.26, pp.32, 2016 (SCI-Expanded)
- LV. **Using Interferon Alfa Before Tyrosine Kinase Inhibitors May Increase Survival in Patients With Metastatic Renal Cell Carcinoma: A Turkish Oncology Group (TOG) Study**
ARTAÇ M., COŞKUN H. Ş., Korkmaz L., Kocer M., Turhal N. S., ENGİN H., Dede I., PAYDAŞ S., Oksuzoglu B., Bozcuk H., et al.
CLINICAL GENITOURINARY CANCER, vol.14, no.4, 2016 (SCI-Expanded)
- LVI. **Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas**
PAYDAŞ S., BAGIR E. K., DEVECİ M. A., GÖNLÜŞEN G.
MEDICAL ONCOLOGY, vol.33, no.8, 2016 (SCI-Expanded)
- LVII. **Management of hemopoietic neoplasias during pregnancy**
PAYDAŞ S.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol.104, pp.52-64, 2016 (SCI-Expanded)
- LVIII. **Pulmonary sarcoidosis induced by the anti-PD-1 monoclonal antibody pembrolizumab or post-immunotherapy granulomatous reaction: which is more appropriate terminology?**
Paydas S.
ANNALS OF ONCOLOGY, vol.27, no.8, pp.1650-1651, 2016 (SCI-Expanded)
- LIX. **Micro-RNA (miRNA) profile in Hodgkin lymphoma: association between clinical and pathological variables**
PAYDAŞ S., AÇIKALIN A., ERGİN M., Celik H., Yavuz B., Tanriverdi K.
MEDICAL ONCOLOGY, vol.33, no.4, 2016 (SCI-Expanded)
- LX. **Risk factors for developing cardiotoxicity of trastuzumab in breast cancer patients: An observational single-centre study**
Gunaldi M., Duman B. B., Afsar C. U., PAYDAŞ S., Erkisi M., KARA İ. O., ŞAHİN B.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.22, no.2, pp.242-247, 2016 (SCI-Expanded)
- LXI. **Brentuximab vedotin use in a jaundiced case with resistant Hodgkin lymphoma**
PAYDAŞ S., OĞUL A., Irili C., GÖKÇAY S.
ANNALS OF HEMATOLOGY, vol.95, no.1, pp.145-146, 2016 (SCI-Expanded)
- LXII. **The clinical characteristics and outcomes of cases with pure ovarian clear cell, mixed type and high-grade serous adenocarcinoma**
Gulec U. K., PAYDAŞ S., GÜZEL A. B., VARDAR M. A., Khatib G., GÜMÜRDÜLÜ D.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, vol.292, no.4, pp.923-929, 2015 (SCI-Expanded)
- LXIII. **CARCINOSARCOMA OF THE UTERUS: A SINGLE INSTITUTION RETROSPECTIVE ANALYSIS OF THE MANAGEMENT AND OUTCOME**
Gulec U. K., PAYDAŞ S., GÜMÜRDÜLÜ D., GÜZEL A. B., VARDAR M. A.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, vol.25, no.9, pp.1092, 2015 (SCI-Expanded)
- LXIV. **Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG)**
İÇLİ F., Altundag K., AKBULUT H., PAYDAŞ S., Basaran G., Saip P., Dogu G. G., Erlap Y., Uslu R., Sevinc A., et al.
BREAST CANCER, vol.22, no.5, pp.480-485, 2015 (SCI-Expanded)
- LXV. **Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma**
PAYDAŞ S., Bagir E., SEYDAOĞLU G., Ercolak V., ERGİN M.
ANNALS OF HEMATOLOGY, vol.94, no.9, pp.1545-1552, 2015 (SCI-Expanded)
- LXVI. **Helicobacter pylori eradication in gastric diffuse large B cell lymphoma**

- PAYDAŞ S.
WORLD JOURNAL OF GASTROENTEROLOGY, vol.21, no.13, pp.3773-3776, 2015 (SCI-Expanded)
- LXVII. **Hepatitis C virus and lymphoma**
Paydas S.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol.93, no.3, pp.246-256, 2015 (SCI-Expanded)
- LXVIII. **Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey**
Salihoglu A., Elverdi T., KARADOGAN I., PAYDAŞ S., ÖZDEMİR E. R., ERDEM G., KARADURMUS N., AKYOL G., KAYNAR L., Yegin Z. A., et al.
ANNALS OF HEMATOLOGY, vol.94, no.3, pp.415-420, 2015 (SCI-Expanded)
- LXIX. **DNA repair gene polymorphisms in B cell non-Hodgkin's lymphoma**
BAHCECI A., PAYDAŞ S., Tanriverdi K., ERGİN M., SEYDAOĞLU G., UCAR G.
TUMOR BIOLOGY, vol.36, no.3, pp.2155-2161, 2015 (SCI-Expanded)
- LXX. **PRAME Expression and Its Clinical Relevance in Hodgkin's Lymphoma**
ERCOLAK V., PAYDAŞ S., BAGIR E., ERGİN M., SEYDAOĞLU G., CELIK H., YAVUZ B., Tanriverdi K., GUNALDI M., AFSAR C. U., et al.
ACTA HAEMATOLOGICA, vol.134, no.4, pp.199-207, 2015 (SCI-Expanded)
- LXXI. **THE EFFECT OF CHEMORADIOTHERAPY ON SURVIVAL IN LOCALLY ADVANCED UNRESECTABLE NON-SMALL CELL LUNG CANCER PATIENTS: EXPERIENCE FROM THE SOUTHEAST REGION OF TURKEY**
Afsar C. U., Karaca F., Gunaldi M., KARA İ. O., Erkisi M., ŞAHİN B., Duman B. B., PAYDAŞ S., Ercolak V.
ACTA MEDICA MEDITERRANEA, vol.31, no.4, pp.883-888, 2015 (SCI-Expanded)
- LXXII. **Alterations of ghrelin with weights and correlation among ghrelin, cytokine and survival in patients receiving chemoradiotherapy for gastrointestinal cancers**
Karaca F., Afsar C. U., Gunaldi M., Erkurt E., Ercolak V., SERTDEMİR Y., PAYDAŞ S.
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, vol.8, no.1, pp.876-882, 2015 (SCI-Expanded)
- LXXIII. **The role of gender in patients with diffuse large B cell lymphoma treated with rituximab-containing regimens: a meta-analysis**
Yildirim M., KAYA V., DEMIRPENCE O., PAYDAŞ S.
ARCHIVES OF MEDICAL SCIENCE, vol.11, no.4, pp.708-714, 2015 (SCI-Expanded)
- LXXIV. **Expression of fibroblast growth factor receptor 1, fibroblast growth factor 2, phosphatidyl inositol 3 phosphate kinase and their clinical and prognostic significance in early and advanced stage of squamous cell carcinoma of the lung**
Afsar C. U., ŞAHİN B., GÜNALDI M., BAGIR E. K., GÜMÜRDÜLÜ D., BURGUT R., ERKISI M., KARA İ. O., PAYDAŞ S., KARACA F., et al.
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, vol.8, no.9, pp.9760-9771, 2015 (SCI-Expanded)
- LXXV. **A Unique Case of Merkel Cell Carcinoma with Ovarian Metastasis**
AÇIKALIN A., PAYDAŞ S., Gulec U. K., Uguz A., GÜMÜRDÜLÜ D.
BALKAN MEDICAL JOURNAL, vol.31, no.4, pp.356-359, 2014 (SCI-Expanded)
- LXXVI. **Abdominal actinomycosis with multiple myeloma: A case report**
Ercolak V., PAYDAŞ S., ERGİN M., Ates B. T., Duman B. B., Gunaldi M., Afsar C. U.
ONCOLOGY LETTERS, vol.8, no.4, pp.1876-1878, 2014 (SCI-Expanded)
- LXXVII. **Extramedullary Myeloid Tumor Involving the Pancreas: A Case Report and Review of the Literature**
PAYDAŞ S., Ozdogu H., Gunaldi M., Haksoyler V., AÇIKALIN A., ERGİN M.
TURKISH JOURNAL OF HEMATOLOGY, vol.31, no.3, pp.295-300, 2014 (SCI-Expanded)
- LXXVIII. **The Role of Radiotherapy Among the Therapeutic Options for Castleman's Disease**
Karaca F., Afsar C. U., Erkurt E., ARSLANTAŞ H. S., Calis E., Ates B. T., Bagir E., ERGİN M., PAYDAŞ S.
TURKISH JOURNAL OF HEMATOLOGY, vol.31, no.2, pp.197-198, 2014 (SCI-Expanded)
- LXXIX. **Prognostic importance of survivin, Ki-67, and topoisomerase II alpha in ovarian carcinoma**
Gulec U. K., GÜMÜRDÜLÜ D., GÜZEL A. B., PAYDAŞ S., SEYDAOĞLU G., AÇIKALIN A., Khatib G., Zeren H., VARDAR M. A., Altintas A.

- ARCHIVES OF GYNECOLOGY AND OBSTETRICS, vol.289, no.2, pp.393-398, 2014 (SCI-Expanded)
- LXXX. **Dasatinib, large granular lymphocytosis, and pleural effusion: Useful or adverse effect?**
Paydas S.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol.89, no.2, pp.242-247, 2014 (SCI-Expanded)
- LXXXI. **Evaluation of Endometrial Thickness and Bone Mineral Density Based on CYP2D6 Polymorphisms in Turkish Breast Cancer Patients Receiving Tamoxifen Treatment**
Gunaldi M., Erkisi M., Afsar C. U., Ercolak V., PAYDAŞ S., KARA İ. O., ŞAHİN B., Gulec U. K., Secilmis A.
PHARMACOLOGY, vol.94, pp.183-189, 2014 (SCI-Expanded)
- LXXXII. **Evaluation of CYP2D6 Polymorphic Types and Their Effect on Tamoxifen Efficacy Among Turkish Tamoxifen Users with Breast Cancer**
Gunaldi M., Erkisi M., Afsar C., Ercolak V., Duman B., PAYDAŞ S., Kara I., ŞAHİN B., TULİ A., Secilmis A.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.24, no.3, pp.157-162, 2014 (SCI-Expanded)
- LXXXIII. **Pancreatic Carcinoma, Thrombosis and Mean Platelet Volume: Single Center Experience from the Southeast Region of Turkey**
Afsar C. U., Gunaldi M., KUM P., Sahin B., Erkisi M., Kara I. O., Paydas S., Duman B. B., Ercolak V., Karaca F., et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.15, no.21, pp.9143-9146, 2014 (SCI-Expanded)
- LXXXIV. **Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients**
ŞAHİN F., SAYDAM G., Comert M., Uz B., Yavuz A. S., Turan E., Yonal I., Atay H., Keltikli E., Turgut M., et al.
TURKISH JOURNAL OF HEMATOLOGY, vol.30, no.4, pp.351-358, 2013 (SCI-Expanded)
- LXXXV. **Sweet Syndrome in a Patient with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Curious Lymphocyte/Neutrophil Fluctuations**
Afsar C. U., PAYDAŞ S., günaldı M., Duman B. B., erçolak V., ZORLUDEMİR S., AÇIKALIN A.
TURKISH JOURNAL OF HEMATOLOGY, vol.30, no.4, pp.413-415, 2013 (SCI-Expanded)
- LXXXVI. **Coexistence of tuberous sclerosis complex and malignant melanoma**
günaldı M., PAYDAŞ S., Afsar C. U., DORAN F.
SINGAPORE MEDICAL JOURNAL, vol.54, no.11, 2013 (SCI-Expanded)
- LXXXVII. **PROGNOSTIC IMPORTANCE OF SURVIVIN, KI-67, AND TOPOISOMERASE II α IN OVARIAN CARCINOMA**
Gulec U. K., Guzel A., Gumurdulu D., Paydas S., Altintas A., Vardar M.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, vol.23, no.8, 2013 (SCI-Expanded)
- LXXXVIII. **Late Onset Epstein Barr Virus Seropositive Posttransplant Lymphoproliferative Disorder in Two Renal Transplant Receivers**
PAYDAŞ S., PAYDAŞ S., BALAL M., AÇIKALIN A., ERGİN M., GÜRKAN E., Baslamisli F.
TURKISH JOURNAL OF HEMATOLOGY, vol.30, no.3, pp.315-320, 2013 (SCI-Expanded)
- LXXXIX. **The Permanent Improvement of Proteinuria and Renal Failure With Colchicine and Enalapril in a Leukemic Patient With Renal Amyloidosis Secondary to Ankylosing Spondylitis: A Review of the Literature**
PAYDAŞ S., PAYDAŞ S., BALAL M.
AMERICAN JOURNAL OF THERAPEUTICS, vol.20, no.4, pp.344-346, 2013 (SCI-Expanded)
- XC. **A Case with Hypothyroidism Following Autologous Stem Cell Transplantation**
Duman B. B., PAYDAŞ S., EVRAN M.
TURKISH JOURNAL OF HEMATOLOGY, vol.30, no.2, pp.221-222, 2013 (SCI-Expanded)
- XCI. **Sweet's syndrome: A revisit for hematologists and oncologists**
Paydas S.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol.86, no.1, pp.85-95, 2013 (SCI-Expanded)
- XCII. **Carbamazepine and Multiple Myeloma: Possible Interaction**
günaldı M., PAYDAŞ S., Afsar C. U., Duman B. B., erçolak V., Haksoyler V.
TURKISH JOURNAL OF HEMATOLOGY, vol.30, no.1, pp.83-84, 2013 (SCI-Expanded)
- XCIII. **Social Support and Hopelessness in Patients with Breast Cancer**
Öztunç G., Yesil P., Paydaş S., Erdogan S.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.14, no.1, pp.571-578, 2013 (SCI-Expanded)

- XCIV. Nephrotic syndrome preceding multiple myeloma: Case report Nefrotik sendroma öncelik eden multipl miyeloma**
PAYDAŞ S., KAYA B., PAYDAŞ S., GÖNLÜŞEN G., BALAL M.
Turkiye Klinikleri Journal of Medical Sciences, vol.33, no.2, pp.591-595, 2013 (SCI-Expanded)
- XCv. Energy drinks and chemotherapy: Can these products cause detrimental effects in cancer patients receiving chemotherapy?**
PAYDAŞ S., sonay Y., avcı A., Duman B. B., Tumkaya E.
EUROPEAN JOURNAL OF INTERNAL MEDICINE, vol.24, no.1, 2013 (SCI-Expanded)
- XCVI. Comparative analysis of CA 125, ferritin, beta-2 microglobulin, lactic dehydrogenase levels in serum and peritoneal fluid in patients with ovarian neoplasia**
Gulec U. K., PAYDAŞ S., GÜZEL A. B., BÜYÜKKURT S., SEYDAOĞLU G., VARDAR M. A.
MEDICAL ONCOLOGY, vol.29, no.4, pp.2937-2943, 2012 (SCI-Expanded)
- XCvII. Secondary malignancy after imatinib therapy: eight cases and review of the literature**
Duman B. B., PAYDAŞ S., Disel U., Besen A., GÜRKAN E.
LEUKEMIA & LYMPHOMA, vol.53, no.9, pp.1706-1708, 2012 (SCI-Expanded)
- XCvIII. Strong cross-talk between angiogenesis and EBV: do we need different treatment approaches in lymphoma cases with EBV and/or high angiogenic capacity**
Paydas S.
MEDICAL ONCOLOGY, vol.29, no.3, pp.2159-2165, 2012 (SCI-Expanded)
- XCIX. Adenosine deaminase activity in patients with ovarian neoplasms**
ÜRÜNSAK İ. F., Gulec U. K., PAYDAŞ S., SEYDAOĞLU G., GÜZEL A. B., VARDAR M. A.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, vol.286, no.1, pp.155-159, 2012 (SCI-Expanded)
- C. Retrospective Analysis of 498 Primary Soft Tissue Sarcomas in a Single Turkish Centre**
Duman B. B., Gunaldi M., Ercolak V., Afsar C. U., ŞAHİN B., Erkisi I. M. K., Kara O., PAYDAŞ S., GÖNLÜŞEN G., SERTDEMİR Y.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.13, no.8, pp.4125-4128, 2012 (SCI-Expanded)
- CI. The Clinical Impact of Low Doses of Dasatinib in Patients with Chronic Myeloid Leukemia**
AKSU S., ŞAHİN F., Uz B., YAVUZ S., Atay H., Kelkitli E., Turgut M., Pehlivan M., Akay M. O., Guray E., et al.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.22, no.1, pp.8-14, 2012 (SCI-Expanded)
- CII. Preoperative evaluation, clinical characteristics, and prognostic factors of nongenital metastatic ovarian tumors: review of 48 patients**
GÜZEL A. B., GULEC U. K., PAYDAŞ S., KHATİB G., GÜMÜRDÜLÜ D., VARDAR M. A., ALTINTAS A.
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, vol.33, no.5, pp.493-497, 2012 (SCI-Expanded)
- CIII. Capecitabine-Induced Hypertriglyceridemia and Hyperglycemia: Two Cases**
Duman B. B., PAYDAŞ S., Tetiker T., Gunaldi M., Afsar C. U., Ercolak V., Haksoyler V., Dilli M. S.
PHARMACOLOGY, vol.90, pp.212-215, 2012 (SCI-Expanded)
- CIV. Bendamustine and rituximab is effective and cost-effective in older cases with aggressive lymphomas?**
Paydas S.
ANNALS OF ONCOLOGY, vol.22, no.12, pp.2694-2695, 2011 (SCI-Expanded)
- CV. Non-Hodgkin's lymphoma in a chronic myelocytic leukemia patient treated with imatinib**
PAYDAŞ S., Duman B. B., ERGİN M.
TURKISH JOURNAL OF HEMATOLOGY, vol.28, no.3, pp.232-234, 2011 (SCI-Expanded)
- CVI. PET CT imaging in extramedullary hematopoiesis and lung cancer surprise in a case with thalassemia intermedia**
PAYDAŞ S., Sargin O., GÖNLÜŞEN G.
TURKISH JOURNAL OF HEMATOLOGY, vol.28, no.1, pp.60-62, 2011 (SCI-Expanded)
- CVII. Short and long term effects of granulocyte colony-stimulating factor during induction therapy in acute myeloid leukemia patients younger than 65: Results of a randomized multicenter phase III trial**
Beksac M., Ali R., Ozcelik T., Ozcan M., Ozcebe O., Bayik M., PAYDAŞ S., BÜYÜKAŞIK Y., İlhan O., Ozkalemkas F., et al.
LEUKEMIA RESEARCH, vol.35, no.3, pp.340-345, 2011 (SCI-Expanded)

- CVIII. **Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma of the Elderly: What We Know So Far**
Castillo J. J., Beltran B. E., Miranda R. N., PAYDAŞ S., Winer E. S., Butera J. N.
ONCOLOGIST, vol.16, no.1, pp.87-96, 2011 (SCI-Expanded)
- CIX. **Hyponatremia Is Not a Rare Adverse Event in Bortezomib-Treated Patients**
PAYDAŞ S.
CHEMOTHERAPY, vol.57, no.5, pp.434-436, 2011 (SCI-Expanded)
- CX. **Smudge cells: Very old history and new conclusions**
Paydas S.
LEUKEMIA RESEARCH, vol.34, no.12, pp.1680, 2010 (SCI-Expanded)
- CXI. **Hepatitis C virus and lymphoma: which is useful-serum or tissue?**
Paydas S.
JOURNAL OF CLINICAL PATHOLOGY, vol.63, no.11, pp.1040, 2010 (SCI-Expanded)
- CXII. **Right and left shifts for age in MDS**
Paydas S.
LEUKEMIA RESEARCH, vol.34, no.4, pp.409-410, 2010 (SCI-Expanded)
- CXIII. **Anti-angiogenic strategies will be a revolution in lymphoma?**
Paydas S.
LEUKEMIA RESEARCH, vol.34, no.4, pp.552, 2010 (SCI-Expanded)
- CXIV. **Severe Pulmonary Toxicity Associated with Fludarabine and Possible Contribution of Rituximab**
Disel U., PAYDAŞ S., Yavuz S., Karakoc E.
CHEMOTHERAPY, vol.56, no.2, pp.89-93, 2010 (SCI-Expanded)
- CXV. **Stewart-Treves Syndrome: Questionable Response to Weekly Paclitaxel**
PAYDAŞ S., Yapar Z., Gonlusen G.
CHEMOTHERAPY, vol.56, no.1, pp.66-68, 2010 (SCI-Expanded)
- CXVI. **The value of F-18-fluorodeoxyglucose positron emission tomography/computed tomography in carcinoma of an unknown primary: diagnosis and follow-up**
Yapar Z., Kibar M., Yapar A. F., Paydaş S., Reyhan M., Kara O., Buyukdereli G., Aydin M., Kelle A. P., Ünal İ., et al.
NUCLEAR MEDICINE COMMUNICATIONS, vol.31, pp.59-66, 2010 (SCI-Expanded)
- CXVII. **Pronostic significance of angiogenic/lymphangiogenic, anti-apoptotic, inflammatory and viral factors in 88 cases with diffuse large B cell lymphoma and review of the literature**
PAYDAŞ S., ERGİN M., SEYDAOĞLU G., ERDOĞAN Ş., Yavuz S.
LEUKEMIA RESEARCH, vol.33, no.12, pp.1627-1635, 2009 (SCI-Expanded)
- CXVIII. **Richter's Transformation; the Cause of Fever of Unknown Origin in a Case with Chronic Lymphocytic Leukemia**
KURTARAN B., PAYDAŞ S., Yavuz S., Candevir A.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.19, no.3, pp.180-183, 2009 (SCI-Expanded)
- CXIX. **Antioxidant enzyme levels in cases with gastrointestinal cancer**
Kekec Y., PAYDAŞ S., Tuli A., Zorludemir S., Sakman G., Seydaoglu G.
EUROPEAN JOURNAL OF INTERNAL MEDICINE, vol.20, no.4, pp.403-406, 2009 (SCI-Expanded)
- CXX. **Disseminated herpes zoster infection in a patient with lymphoma**
KURTARAN B., PAYDAŞ S., Candevir A., Komur S., Aksu H. S. Z.
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.39, no.3, pp.479-482, 2009 (SCI-Expanded)
- CXXI. **Castleman-like reaction due to toxic substance ingestion**
PAYDAŞ S., Ergin M., Sikgenc M., Bicakci K., Kiroglu M.
EUROPEAN JOURNAL OF INTERNAL MEDICINE, vol.20, no.3, pp.328-330, 2009 (SCI-Expanded)
- CXXII. **Regression of chronic lymphocytic leukemia with aromatase inhibitor-letrozole?**
Paydas S.
LEUKEMIA RESEARCH, vol.33, no.4, pp.566-567, 2009 (SCI-Expanded)
- CXXIII. **Efficacy of pneumatic compression and low-level laser therapy in the treatment of postmastectomy lymphoedema: a randomized controlled trial**
Kozanoglu E., BAŞARAN S., PAYDAŞ S., SARPEL T.

- CLINICAL REHABILITATION, vol.23, no.2, pp.117-124, 2009 (SCI-Expanded)
- CXXXIV. **Dramatic response with capecitabine after cranial radiation to the brain parenchymal and leptomeningeal metastases from lung cancer**
PAYDAŞ S., Bicakci K., Yavuz S.
EUROPEAN JOURNAL OF INTERNAL MEDICINE, vol.20, no.1, pp.96-99, 2009 (SCI-Expanded)
- CXXXV. **The prognostic significance of VEGF-C and VEGF-A in non-Hodgkin lymphomas**
PAYDAŞ S., SEYDAOĞLU G., ERGİN M., ERDOĞAN Ş., Yavuz S.
LEUKEMIA & LYMPHOMA, vol.50, no.3, pp.366-373, 2009 (SCI-Expanded)
- CXXXVI. **Is everything known in all faces of iceberg in PRAME?**
Paydas S.
LEUKEMIA RESEARCH, vol.32, no.9, pp.1356-1357, 2008 (SCI-Expanded)
- CXXXVII. **Prognostic significance of EBV-LMP1 and VEGF-A expressions in non-Hodgkin's lymphomas**
PAYDAŞ S., ERGİN M., ERDOĞAN Ş., SEYDAOĞLU G.
LEUKEMIA RESEARCH, vol.32, no.9, pp.1424-1430, 2008 (SCI-Expanded)
- CXXXVIII. **Motor neuron disease associated with multiple myeloma**
Koc F., Paydas S., Yerdelen D., Demirkiran M.
INTERNATIONAL JOURNAL OF NEUROSCIENCE, vol.118, no.3, pp.337-341, 2008 (SCI-Expanded)
- CXXXIX. **Thrombospondin-1 (TSP-1) and Survivin (S) expression in non-Hogkin's lymphomas**
PAYDAŞ S., ERGİN M., ERDOĞAN Ş., SEYDAOĞLU G., Yavuz S., Disel U.
LEUKEMIA RESEARCH, vol.32, no.2, pp.243-250, 2008 (SCI-Expanded)
- CXXX. **Tailored thromboprophylaxis for patients with multiple myeloma treated by IMiDs**
Paydas S.
LEUKEMIA & LYMPHOMA, vol.49, no.8, pp.1644-1645, 2008 (SCI-Expanded)
- CXXXI. **Survivin and EPR-1 expression in acute leukemias: Prognostic significance and review of the literature**
Oto O. A., Paydas S., Tanriverdi K., Seydaoglu G., Yavuz S., Disel U.
LEUKEMIA RESEARCH, vol.31, no.11, pp.1495-1501, 2007 (SCI-Expanded)
- CXXXII. **PRAME mRNA levels in cases with chronic leukemia: Clinical importance and review of the literature**
Paydas S., Tanriverdi K., Yavuz S., Seydaoglu G.
LEUKEMIA RESEARCH, vol.31, no.3, pp.365-369, 2007 (SCI-Expanded)
- CXXXIII. **Amphotericin B deoxycholate (d-AMB) use in cases with febrile neutropenia and fungal infections: lower toxicity with suitable premedication**
Oto O. A., Paydas S., Disel U., Yavuz S., Seydaoglu G.
MYCOSES, vol.50, no.2, pp.135-139, 2007 (SCI-Expanded)
- CXXXIV. **Cyclooxygenase-2 expression in non-Hodgkin's lymphomas**
Paydas S., Ergin M., Erdogan S., Seydaoglu G.
LEUKEMIA & LYMPHOMA, vol.48, no.2, pp.389-395, 2007 (SCI-Expanded)
- CXXXV. **Gravin gene expression in acute leukaemias: Clinical importance and review of the literature**
Yildirim M., Paydas S., Tanriverdi K., Seydaoglu G., Disel U., Yavuz S.
LEUKEMIA & LYMPHOMA, vol.48, no.6, pp.1167-1172, 2007 (SCI-Expanded)
- CXXXVI. **Granulocytic sarcoma: 32 cases and review of the literature**
Paydas S., Zorludemir S., Ergin M.
LEUKEMIA & LYMPHOMA, vol.47, no.12, pp.2527-2541, 2006 (SCI-Expanded)
- CXXXVII. **Can survivin expression predict the response to bortezomib in cases with mantle cell lymphoma?**
Paydas S.
LEUKEMIA & LYMPHOMA, vol.47, no.11, pp.2412-2413, 2006 (SCI-Expanded)
- CXXXVIII. **Transfusion-associated graft-versus-host disease**
OTO O. A., Paydas S., Baslamisli F., TUNCER I., Ergin M., Kalakoc E., DISEL U., YAVUZ S., KOESE F., Tasova Y.
EUROPEAN JOURNAL OF INTERNAL MEDICINE, vol.17, no.3, pp.151-156, 2006 (SCI-Expanded)
- CXXXIX. **Bilateral ear Sweet's syndrome in a case with relapse acute myeloblastic leukemia**
DISEL U., Paydas S., Yavuz S., TUNCER I., Alpay R.

- LEUKEMIA RESEARCH, vol.30, no.3, pp.364, 2006 (SCI-Expanded)
- CXL. **Young age MDS: Differences between Western and Eastern countries**
Paydas S.
LEUKEMIA RESEARCH, vol.30, no.3, pp.362, 2006 (SCI-Expanded)
- CXLI. **Feasibility of FLAG-IDA regimen in cases with relapsed/refractory acute leukemia cases**
Paydas S., Yavuz S., Disel U.
ANNALS OF HEMATOLOGY, vol.85, no.1, pp.63, 2006 (SCI-Expanded)
- CXLII. **Autoimmune thyroid dysfunction after hematopoietic stem cell transplantation**
Paydas S.
BONE MARROW TRANSPLANTATION, vol.36, no.3, pp.277, 2005 (SCI-Expanded)
- CXLIII. **PRAME mRNA levels in cases with acute leukemia: Clinical importance and future prospects**
Paydas S., Tanriverdi K., Yavuz S., Disel U., Baslamisli F., Burgut R.
AMERICAN JOURNAL OF HEMATOLOGY, vol.79, no.4, pp.257-261, 2005 (SCI-Expanded)
- CXLIV. **Granulocytic sarcoma of the heart: Extramedullary relapse of acute myeloblastic leukemia after allogeneic stem cell transplantation successfully treated by chemotherapy alone**
Kara I., Sahin B., Paydas S., Kara B.
LEUKEMIA & LYMPHOMA, vol.46, no.7, pp.1081-1084, 2005 (SCI-Expanded)
- CXLV. **Different glomerulopathies accompanying non-small-cell lung cancer**
Paydas S., SOYDAS B., Paydas S., BALAL M., ERDOGAN S., TUNCER I.
MOUNT SINAI JOURNAL OF MEDICINE, vol.72, no.4, pp.279-281, 2005 (SCI-Expanded)
- CXLVI. **VEGF-C expression in breast cancer: Clinical importance**
Yavuz S., Paydas S., Disel U., Zorludemir S., Erdogan S.
ADVANCES IN THERAPY, vol.22, no.4, pp.368-380, 2005 (SCI-Expanded)
- CXLVII. **Bilateral choroidal infiltration from indolent non-Hodgkin's lymphoma: A rapid course with poor prognosis**
Ozcan A. A., Paydas S., Soylu M., Yavuz S.
LEUKEMIA & LYMPHOMA, vol.46, no.4, pp.615-617, 2005 (SCI-Expanded)
- CXLVIII. **Post transplant lymphoproliferative disease: detection of tumor by Tc99m sestaMIBI and treatment with rituximab.**
Paydas S., Yapar Z., Ergin M., Guney İ. B., Disel U., Yavuz S.
Bone marrow transplantation, vol.35, no.3, pp.317-8, 2005 (SCI-Expanded)
- CXLIX. **Hepatitis C virus infection and lymphomas**
Paydas S.
INTERNATIONAL JOURNAL OF CANCER, vol.113, no.2, pp.338, 2005 (SCI-Expanded)
- CL. **Glomerular disease in patients with malignant disease: Four cases and review of literature**
Paydas S., BALAL M., Paydas S., OTO O., GONLUSEN G.
RENAL FAILURE, vol.27, no.1, pp.1-6, 2005 (SCI-Expanded)
- CLI. **Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients**
Kara I., Sahin B., Paydas S., Cetiner S.
SAUDI MEDICAL JOURNAL, vol.25, no.11, pp.1587-1592, 2004 (SCI-Expanded)
- CLII. **Scrotal ulceration associated with ATRA**
Paydas S.
AMERICAN JOURNAL OF HEMATOLOGY, vol.77, no.2, pp.206-207, 2004 (SCI-Expanded)
- CLIII. **Detection of hepatitis C virus RNA in paraffin-embedded tissues from patients with non-Hodgkin's lymphoma**
Paydas S., Ergin M., Tanriverdi K., Yavuz S., Disel U., Kilic N., Erdogan S., Sahin B., TUNCER I., Burgut R.
AMERICAN JOURNAL OF HEMATOLOGY, vol.76, no.3, pp.252-257, 2004 (SCI-Expanded)
- CLIV. **Lymphadenopathy in adult-onset Still's disease mimicking peripheral T-cell lymphoma**
Soy M., Ergin M., Paydas S.
CLINICAL RHEUMATOLOGY, vol.23, no.1, pp.81-82, 2004 (SCI-Expanded)

- CLV. **Prostatic hypertrophy and prostatic infiltration in small lymphocytic lymphoma**
Yavuz S., Paydas S., Disel U., Zorludemir S., Erdogan S.
LEUKEMIA & LYMPHOMA, vol.45, no.1, pp.201-202, 2004 (SCI-Expanded)
- CLVI. **VEGF-C expression in breast cancer**
Yavuz S., PAYDAŞ S., ZORLUDEMİR S., Disel U., ŞAHİN B.
ANNALS OF ONCOLOGY, vol.15, pp.24, 2004 (SCI-Expanded)
- CLVII. **Fludarabine as the possible cause of acute myelofibrosis**
Paydas S., Disel U., Yavuz S., Ergin M.
HEMATOLOGY JOURNAL, vol.5, no.3, pp.283-284, 2004 (SCI-Expanded)
- CLVIII. **Ovarian granulocytic sarcoma**
Yavuz S., Paydas S., Disel U., Erdogan S.
LEUKEMIA & LYMPHOMA, vol.45, no.1, pp.183-185, 2004 (SCI-Expanded)
- CLIX. **Fludarabine-induced hemolytic anemia: successful treatment by rituximab**
Paydas S.
HEMATOLOGY JOURNAL, vol.5, no.1, pp.81-83, 2004 (SCI-Expanded)
- CLX. **Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin's lymphoma**
Hazar B., Paydas S., Zorludemir S., Sahin B., TUNCER I.
LEUKEMIA & LYMPHOMA, vol.44, no.12, pp.2089-2093, 2003 (SCI-Expanded)
- CLXI. **Successful rituximab therapy for hemolytic anemia associated with relapsed splenic marginal zone lymphoma with leukemic phase**
Paydas S., Yavuz S., Disel U., Sahin B., Ergin M.
LEUKEMIA & LYMPHOMA, vol.44, no.12, pp.2165-2166, 2003 (SCI-Expanded)
- CLXII. **Anti-HCV and HCV-RNA prevalence and clinical correlations in cases with non-Hodgkin's lymphoma**
Paydas S., Kilic B., Yavuz S., Disel U., Tanriverdi K., Sahin B., Burgut R.
AMERICAN JOURNAL OF HEMATOLOGY, vol.74, no.2, pp.89-93, 2003 (SCI-Expanded)
- CLXIII. **Survivin and aven: two distinct antiapoptotic signals in acute leukemias**
Paydas S., Tanriverdi K., Yavuz S., Disel U., Sahin B., Burgut R.
ANNALS OF ONCOLOGY, vol.14, no.7, pp.1045-1050, 2003 (SCI-Expanded)
- CLXIV. **Hepatitis B virus reactivation during fludarabine therapy in non-Hodgkin's lymphoma**
Yavuz S., Paydas S., Disel U., Sahin B.
LEUKEMIA & LYMPHOMA, vol.44, no.7, pp.1249-1250, 2003 (SCI-Expanded)
- CLXV. **Serous retinal detachment in a case with chronic lymphocytic leukemia: no response to systemic and local treatment**
Paydas S., Soylu M., Disel U., Yavuz S., Sahin B., Ersoz C., Ergin M., Uguz A.
LEUKEMIA RESEARCH, vol.27, no.6, pp.557-559, 2003 (SCI-Expanded)
- CLXVI. **Mucormycosis of the tongue in a patient with acute lymphoblastic leukemia: A possible relation with use of a tongue depressor**
Paydas S., Yavuz S., Disel U., Yildirim M., Besen A., Sahin B., Gumurdulu D., Yuce E.
AMERICAN JOURNAL OF MEDICINE, vol.114, no.7, pp.618-620, 2003 (SCI-Expanded)
- CLXVII. **Extramedullary relapse in the pleura in acute promyelocytic leukemia**
Disel U., Yavuz S., Paydas S., Sahin B., Zeren H.
LEUKEMIA & LYMPHOMA, vol.44, no.1, pp.189-191, 2003 (SCI-Expanded)
- CLXVIII. **Vasculitis associated with all trans retinoic acid (ATRA) in a case with acute promyelocytic leukemia**
Paydas S., Yavuz S., Disel U., Sahin B., Canbolat T., Tuncer İ.
LEUKEMIA & LYMPHOMA, vol.44, no.3, pp.547-548, 2003 (SCI-Expanded)
- CLXIX. **HCV and tumors of the immune system**
Paydas S.
LEUKEMIA RESEARCH, vol.26, no.12, pp.1141, 2002 (SCI-Expanded)
- CLXX. **Granulomatous reaction after chemotherapy for Hodgkin's disease**
Paydas S., Yavuz S., Disel U., Zeren H., Hasturk S., HANTA I., Ergin M., Sahin B.

- LEUKEMIA RESEARCH, vol.26, no.10, pp.967-970, 2002 (SCI-Expanded)
- CLXXI. **Bone marrow necrosis: Clinicopathologic analysis of 20 cases and review of the literature**
Paydas S., Ergin M., Baslamisli F., Yavuz S., Zorludemir S., Sahin B., Bolat F.
AMERICAN JOURNAL OF HEMATOLOGY, vol.70, no.4, pp.300-305, 2002 (SCI-Expanded)
- CLXXII. **Sickle cell anemia and hematological neoplasias**
Paydas S.
LEUKEMIA & LYMPHOMA, vol.43, no.7, pp.1431-1434, 2002 (SCI-Expanded)
- CLXXIII. **Cutaneous lesions and chronic myelocytic leukemia (CML) in progression**
Paydas S.
ANNALS OF HEMATOLOGY, vol.81, no.3, pp.178, 2002 (SCI-Expanded)
- CLXXIV. **Vascular endothelial growth factor (VEGF) expression in plasmacytoma**
Paydas S., Zorludemir S., Baslamisli F., TUNCER İ.
LEUKEMIA & LYMPHOMA, vol.43, no.1, pp.139-143, 2002 (SCI-Expanded)
- CLXXV. **MUC1 expression in plasmacytoma**
Paydas S., Sahin B., Gonlusen G., Hazar B., Zorludemir S.
LEUKEMIA RESEARCH, vol.25, no.3, pp.221-225, 2001 (SCI-Expanded)
- CLXXVI. **Vasculitis and leukemia**
Paydas S., Zorludemir S., Sahin B.
LEUKEMIA & LYMPHOMA, vol.40, pp.105-113, 2000 (SCI-Expanded)
- CLXXVII. **Leukaemia cutis and leukaemic vasculitis**
Paydas S., Zorludemir S.
BRITISH JOURNAL OF DERMATOLOGY, vol.143, no.4, pp.773-779, 2000 (SCI-Expanded)
- CLXXVIII. **The association of thyrotoxicosis and chronic lymphoproliferative disorders**
Paydas S., Sahin B., Hazar B., Yavuz S.
LEUKEMIA & LYMPHOMA, vol.38, pp.131-135, 2000 (SCI-Expanded)
- CLXXIX. **Clinical significance and frequency of Blastocystis hominis in Turkish patients with hematological malignancy**
Tasova Y., Sahin B., Koltas S., Paydas S.
ACTA MEDICA OKAYAMA, vol.54, no.3, pp.133-136, 2000 (SCI-Expanded)
- CLXXX. **Lymphomatous skin infiltration at the site of previous varicella zoster virus infection in a patient with T cell lymphoma**
Paydas S., Sahin B., Yavuz S., TUNCER I., Gonlusen G.
LEUKEMIA & LYMPHOMA, vol.37, pp.229-234, 2000 (SCI-Expanded)
- CLXXXI. **Granulocytic sarcoma as the cause of giant abdominal mass: diagnosis by fine needle aspiration and review of the literature**
Paydas S., Hazar B., Sahin B., Gonlusen G.
LEUKEMIA RESEARCH, vol.24, no.3, pp.267-269, 2000 (SCI-Expanded)
- CLXXXII. **Sweet's syndrome accompanying leukaemia: seven cases and review of the literature**
Paydas S., Sahin B., Zorludemir S.
LEUKEMIA RESEARCH, vol.24, no.1, pp.83-86, 2000 (SCI-Expanded)
- CLXXXIII. **Postmastectomy malignant lymphoma**
Paydas S., Sahin B., Yavuz S., Gonlusen G.
LEUKEMIA & LYMPHOMA, vol.36, pp.417-421, 2000 (SCI-Expanded)
- CLXXXIV. **Interesting morphologic finding in T-cell acute lymphoblastic leukemia**
Paydas S.
DIAGNOSTIC CYTOPATHOLOGY, vol.21, no.1, pp.55-56, 1999 (SCI-Expanded)
- CLXXXV. **Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders in Southern Turkey**
Paydas S., Kilic B., Sahin B., Bugdayci R.
BRITISH JOURNAL OF CANCER, vol.80, no.9, pp.1303-1305, 1999 (SCI-Expanded)
- CLXXXVI. **All trans retinoic acid as the possible cause of necrotizing vasculitis**

- Paydas S., Sahin B., Zorludemir S., Hazar B.
LEUKEMIA RESEARCH, vol.22, no.7, pp.655-657, 1998 (SCI-Expanded)
- CLXXXVII. **Bone marrow necrosis in antiphospholipid syndrome**
Paydas S., Kocak R., Zorludemir S., Baslamisli F.
JOURNAL OF CLINICAL PATHOLOGY, vol.50, no.3, pp.261-262, 1997 (SCI-Expanded)
- :LXXXVIII. **p53 protein expression in gastrointestinal lymphomas**
Hazar B., Paydas S., Zorludemir S., Sahin B., TUNCER I.
ONCOLOGY, vol.54, no.1, pp.84-87, 1997 (SCI-Expanded)
- CLXXXIX. **Role of granulocyte colony-stimulating factor in the treatment of mucormycosis**
Sahin B., Paydas S., Cosar E., Bicakci K., Hazar B.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, vol.15, no.11, pp.866-869, 1996 (SCI-Expanded)
- CXC. **Malignant lymphoma with severe hypoglycaemia**
Camci C., Paydas S., Sahin B., Cosar E.
EUROPEAN JOURNAL OF CANCER, no.12, pp.2185, 1996 (SCI-Expanded)
- CXCI. **Younger age observation in myelodysplastic syndrome**
Paydas S., KOCAK R.
LEUKEMIA RESEARCH, vol.20, no.4, pp.367, 1996 (SCI-Expanded)
- CXCII. **INTRACELLULAR GLUTATHIONE CONTENT IN LEUKEMIAS**
PAYDAS S., YUREGIR G., SAHIN B., SEYREK E., BURGUT R.
ONCOLOGY, vol.52, no.2, pp.112-115, 1995 (SCI-Expanded)
- CXCIII. **P53 PROTEIN EXPRESSION IN LEUKEMIAS**
PAYDAS S.
ACTA ONCOLOGICA, vol.34, no.1, pp.23-26, 1995 (SCI-Expanded)
- CXCIV. **FLOW CYTOMETRIC DNA ANALYSIS IN PRIMARY GASTROINTESTINAL LYMPHOMA**
PAYDAS S., DINCOL D., GILMANSACHS A., TUNCER İ., ZORLUDEMİR S., ERSOZ C., KUCUK O.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, vol.13, no.3, pp.229-232, 1994 (SCI-Expanded)
- CXCV. **SERUM LEVELS OF TUMOR-NECROSIS-FACTOR IN SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK**
SOYLU L., OZCAN C., CETIK F., PAYDAS S., KIROGLU M. M., AYDOGAN B., SARGIN O., OZSAHINOGLU C., SEYREK E.
AMERICAN JOURNAL OF OTOLARYNGOLOGY, vol.15, no.4, pp.281-285, 1994 (SCI-Expanded)
- CXCVI. **DNA-PLOIDY, PROLIFERATIVE ACTIVITY, AND CONCANAVALIN-A REACTIVITY IN BREAST-CANCER**
PAYDAS S., SARPEL S., GILMANSACHS A., TUNCER I., PEHLIVAN S., TUNALI N., ZORLUDEMİR S., BURGUT R., KUCUK O.
JOURNAL OF SURGICAL ONCOLOGY, vol.56, no.1, pp.21-24, 1994 (SCI-Expanded)
- CXCVII. **COEXISTENCE OF DIABETES-INSIPIDUS AND IDIOPATHIC THROMBOCYTOPENIC PURPURA**
PAYDAS S., PAYDAS S.
INTERNATIONAL JOURNAL OF HEMATOLOGY, vol.56, no.1, pp.103-105, 1992 (SCI-Expanded)
- CXCVIII. **PERNICIOUS-ANEMIA IN TURKEY**
KOCAK R., PAYDAS S.
INTERNATIONAL JOURNAL OF HEMATOLOGY, vol.55, no.2, pp.117-119, 1992 (SCI-Expanded)
- CXCIX. **FERRITIN LEVELS IN MALIGNANT EFFUSIONS - A USEFUL MARKER**
PAYDAS S., SARGIN O., OZBEK S., GURBUZ E.
EUROPEAN JOURNAL OF CANCER, vol.26, no.8, pp.919, 1990 (SCI-Expanded)
- CC. **NON-HODGKINS LYMPHOMAS IN TURKEY**
SARPEL S., PAYDAS S., TUNCER I., VARINLI S., KOKSAL M., AKOGLU T.
CANCER, vol.62, no.8, pp.1653-1657, 1988 (SCI-Expanded)
- CCI. **INCOMPLETE BEHCETS-SYNDROME WITH UNUSUAL MANIFESTATIONS**
AKOGLU T., PAYDAS S., SARPEL S., TUNALI N., TUNCER I.
ANNALS OF THE RHEUMATIC DISEASES, vol.46, no.8, pp.632-633, 1987 (SCI-Expanded)

Articles Published in Other Journals

- I. **Issues with the targeted therapy of non-small cell lung cancer with thyroid metastases: A case report**
Bayram E., Toyran T., Güney İ. B., Uğuz A. H., Gümürdülü D., Paydaş S.
Medicine International, vol.3, no.6, 2023 (Peer-Reviewed Journal)
- II. **Transfüzyon ilişkili GVHH**
YASLIKAYA Ş., BİTER S., KOBA M., ERDOĞAN M., TOZLUKLU N. N., IŞIK B., PAYDAŞ S.
ARSIV KAYNAK TARAMA DERGİSİ, vol.32, no.2, pp.91-96, 2023 (Peer-Reviewed Journal)
- III. **Primary mediastinal large B-cell lymphoma that occurs in an unexpected localization**
Inceman M., Pehlivan U. A., Toyran T., ÖZDEK R., Paydas S.
Cukurova Medical Journal, vol.48, no.1, pp.304-305, 2023 (ESCI)
- IV. **The effect of clinicopathological features on prognosis in malignant ovarian germ cell tumors**
Sadigova Y., seyfettinoglu s., Kucukgoz Gulec U., Khatib G., güzel a. b., GÜMÜRDÜLÜ D., Paydas S., vardar M.
Cukurova Medical Journal, vol.48, no.1, pp.54-63, 2023 (ESCI)
- V. **Effect of microsatellite instability on histopathological parameters and prognosis in colon cancers**
TOYRAN T., ERDOĞAN K. E., KILIÇ BAĞIR E., AÇIKALIN A., AKSIN M., PAYDAŞ S., METE B., ERDOĞAN Ş.
CUKUROVA MEDICAL JOURNAL, vol.48, no.1, pp.1-10, 2023 (ESCI)
- VI. **Systemic therapy response evaluation in prostate carcinoma with [Ga-68]Ga-PSMA-11 PET/CT**
Kucuker K. A., Yapar Z., Güney İ. B., Paydaş S.
EGYPTIAN JOURNAL OF RADIOLOGY AND NUCLEAR MEDICINE, vol.53, no.1, 2022 (ESCI)
- VII. **Sarcoid-Like Reaction Mimicking Disease Progression Associated with Nivolumab in a Case with Malignant Mesothelioma: Is There a Solution for This Dilemma?**
Paydaş S., Tuncer I., Güzel A. B., Parsak C. K., Güney İ. B.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, vol.6, no.1, pp.89-91, 2022 (ESCI)
- VIII. **Prognostic Importance of DUSP22 (Dual Specificity Phosphatase 22) Gene Expression in Low-Grade Lymphomas**
Paydaş S., Kılıç Bağır E., Ergin M., Seydaoğlu G., Büyüksimşek M., Boz A.
Eurasian Journal of Medicine and Oncology, vol.5, no.4, pp.327-331, 2021 (ESCI)
- IX. **Systemic Aspergillosis: Radiological Findings in a Case With Diffuse Large B Cell Lymphoma Treated by Ibrutinib**
PEHLİVAN U. A., ONAN H. B., BAYRAM E., KESER C., PAYDAŞ S.
CUREUS, 2021 (ESCI)
- X. **The Assessment of Volume Status with Body Composition Monitor in Cancer Patients**
PAYDAŞ S., ÖZONUR H., PAYDAŞ S., KAYA B., EFE C.
Eurasian Journal of Medicine and Oncology, vol.5, no.2, pp.246-250, 2021 (Peer-Reviewed Journal)
- XI. **KEMOTERAPİ ALAN MEME KANSERLİ HASTALARA BAKIM VEREN YAKINLARININ YAŞAM KALİTESİ**
ESKİMEZ Z., KÖSE TOSUNÖZ İ., ÖZTUNÇ G., YEŞİL DEMİRCİ P., PAYDAŞ S., KUMAŞ G.
Sağlık Bilimleri Dergisi, vol.30, no.1, pp.21-30, 2021 (Peer-Reviewed Journal)
- XII. **The assesment of volume status with body composition monitor in cancer patients**
Paydaş S., Özönur H., Paydaş S., Kaya B., Efe C.
EURASIAN JOURNAL OF MEDICAL INVESTIGATION, vol.40, no.5(2), pp.246-250, 2021 (Peer-Reviewed Journal)
- XIII. **The Effect of Inflammatory Markers on Survival in Advanced Biliary Tract Carcinoma Treated with Gemcitabine/Oxaliplatin Regimen**
Buyuksimsek M., Kidi M. M., Ogul A., Mirili C., PAYDAŞ S.
JOURNAL OF GASTROINTESTINAL CANCER, vol.52, no.1, pp.249-255, 2021 (ESCI)
- XIV. **Assessment of Prognostic Factors and Adjuvant Treatment Modalities in Adult Head and Neck Soft Tissue Sarcoma Patients Treated With Upfront Surgery**
Akagunduz B., Telli T. A., SEZGİN GÖKSU S., YILDIRIM H. Ç., Ozer M., Aydin S. G., Ozyurt N., Karacin C., PAYDAŞ S., Dogan M.
CUREUS, vol.13, no.2, 2021 (ESCI)

- XV. **Kemoterapi Alan Meme Kanserli Hastalara Bakım Veren Yakınlarının Yaşam Kalitesi**
ESKİMEZ Z., KÖSE TOSUNÖZ İ., ÖZTUNÇ G., YEŞİL DEMİRCİ P., PAYDAŞ S., KUMAŞ G.
Sağlık Bilimleri Dergisi, vol.30, no.1, pp.21-30, 2021 (Peer-Reviewed Journal)
- XVI. **Tamoksifen Kullanan Hastaların Jinekolojik Yönden Değerlendirilmesi**
Küçükgöz Güleç Ü., Paydaş S., Güzel A. B.
Arşiv Kaynak Tarama Dergisi, vol.30, no.1, pp.45-51, 2021 (Peer-Reviewed Journal)
- XVII. **Tafro syndrome from a single center outside Japan: 3 cases and review of the literature**
KUZU T., PAYDAŞ S., KURTARAN B., PAYDAŞ S., kılıç bağır e., ERGİN M.
HEMATOLOGY ONCOLOGY CURRENT RESEARCH, no.3, pp.1005, 2020 (Peer-Reviewed Journal)
- XVIII. **Inflammatory Markers Predicting Pathological Complete Response in Cases with Breast Cancer Treated by Neoadjuvant Chemotherapy**
Buyuksimsek M., Ogul A., Mirilli C., PAYDAŞ S.
EUROPEAN JOURNAL OF BREAST HEALTH, vol.16, no.4, pp.229-234, 2020 (ESCI)
- XIX. **Predictive Biomarkers in Late Onset Neutropenia Associated with Rituximab**
OĞUL A., PAYDAŞ S., YETİŞİR A. E., MİRİLİ C., BÜYÜKŞİMŞEK M.
Eurasian Journal of Medical Investigation, vol.4, no.4, pp.428-432, 2020 (Peer-Reviewed Journal)
- XX. **Clinical Features and Treatment Results of Metastatic Breast Cancer Patients: A Single Center Experience**
BÜYÜKŞİMŞEK M., PAYDAŞ S., Togun M., yetişir a. e., MİRİLİ C., OĞUL A., TOHUMCUOĞLU M.
ANADOLU KLİNİĞİ TIP BİLİMLERİ DERGİSİ, vol.25, no.2, pp.75-85, 2020 (Peer-Reviewed Journal)
- XXI. **LENFOMA HASTALARINDA HEPATİT B VE C PREVALANSININ DEĞERLENDİRİLMESİ**
BÜYÜKŞİMŞEK M., TOĞUN M., yetişir a. e., MİRİLİ C., OĞUL A., TOHUMCUOĞLU M., PAYDAŞ S.
Namık Kemal Tıp Dergisi, vol.8, no.1, pp.48-51, 2020 (Peer-Reviewed Journal)
- XXII. **Obez endometroid endometrial kanserli olgulara pelvik lenfadenektomiye paraaortik lenfadenektomi eklenmesinin sağkalıma etkisi**
KHATİB G., VARDAR M. A., GÜZEL A. B., KÜÇÜKGÖZ GÜLEÇ Ü., SEYFETTİNOĞLU S., BAYAT B., KILIÇ BAĞIR E., PAYDAŞ S.
Cukurova Medical Journal, vol.45, no.1, pp.134-140, 2020 (ESCI)
- XXIII. **Pulmonary hyalinizing granuloma with castleman**
AÇIKALIN A., KILIÇ BAĞIR E., AKSIN M., GÜMÜRDÜLÜ D., ERGİN M., PAYDAŞ S.
Journal of Current Pathology, vol.4, no.1, pp.5, 2020 (Peer-Reviewed Journal)
- XXIV. **Prognostic significance of PRAME (preferentially expressed antigen of melanoma) expression in breast cancer**
DALCI K., Kecec Y., PAYDAŞ S., ZORLUDEMİR S., ERGİN M., Tanriverdi K., SEYDAOĞLU G., Ucar G.
CUKUROVA MEDICAL JOURNAL, vol.45, no.3, pp.1202-1209, 2020 (ESCI)
- XXV. **Dynamic prognostic nutritional index could be a novel predictor of survival in lung cancer patients treated with nivolumab**
MİRİLİ C., PAYDAŞ S., OĞUL A., GÖKÇAY S., BÜYÜKŞİMŞEK M., YETİŞİR A. E., TOHUMCUOĞLU M., Karaalioglu B.
ANNALS OF CLINICAL AND ANALYTICAL MEDICINE, vol.11, pp.1-6, 2020 (ESCI)
- XXVI. **Factors predicting prognosis with oncology patients followed in the intensive care unit**
OĞUL A., PAYDAŞ S., KARAKOÇ E., ŞEYDAOĞLU G., BÜYÜKŞİMŞEK M.
CUKUROVA MEDICAL JOURNAL, vol.45, no.4, pp.1267-1275, 2020 (ESCI)
- XXVII. **The survival impact of adding paraaortic lymphadenectomy to pelvic lymphadenectomy in the obese endometrioid endometrial cancer cases**
Khatib G., VARDAR M. A., GÜZEL A. B., KÜÇÜKGÖZ GÜLEÇ Ü., Seyfettinoglu S., Bayat B., BAĞIR KILIÇ E., PAYDAŞ S.
CUKUROVA MEDICAL JOURNAL, vol.45, no.1, pp.134-140, 2020 (ESCI)
- XXVIII. **LONG-TERM OUTCOME OF SOFT TISSUE SARCOMAS TREATED WITH MESNA-DOXORUBICIN-IFOSFAMID-DACARBAZINE REGIMEN (MAID): A RETROSPECTIVE STUDY FROM A SINGLE INSTITUTION**
MİRİLİ C., PAYDAŞ S., BÜYÜKŞİMŞEK M., TOHUMCUOĞLU M., yetişir a. e., OĞUL A.
Namık Kemal Medical Journal (NKMJ), vol.7, no.3, pp.271-278, 2019 (Peer-Reviewed Journal)

- XXIX. **LONG-TERM OUTCOME OF SOFT TISSUE SARCOMAS TREATED WITH MESNA-DOXORUBICIN-IFOSFAMID-DACARBAZINE REGIMEN (MAID): A RETROSPECTIVE STUDY FROM A SINGE INSTITUTION**
MIRILI C., PAYDAŞ S., BUYUKSIMSEK M., TOHUMCUOĞLU M.
Namık Kemal Tıp Dergisi, 2019 (Peer-Reviewed Journal)
- XXX. **Clinic, Prognostic and Predictive Value of Circulating Tumor DNA in Lymphomas**
PAYDAŞ S.
LLM Dergi, vol.3, no.3, pp.45-50, 2019 (Peer-Reviewed Journal)
- XXXI. **Pancreatic plasmacytoma: A rare but important entity for gastroenterologists, oncologists and hematologists**
PAYDAŞ S.
Journal of Oncological Sciences, vol.5, no.3, pp.109-111, 2019 (Peer-Reviewed Journal)
- XXXII. **Are Uterine Grade 3 Endometrioid Adenocarcinoma and Carcinosarcoma Really Clinically Similar?**
Gulec U. K., PAYDAŞ S., GÜMÜRDÜLÜ D., GÜZEL A. B., Bağir E. K., VARDAR M. A.
INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY, vol.17, no.2, 2019 (ESCI)
- XXXIII. **Prognostic significance of dynamic inflammatory indexes in cases renal cell cancer treated by tyrosine kinase inhibitor (TKI)**
MIRILI C., PAYDAŞ S., YILMAZ A., OGUL A., BUYUKSIMSEK M., YETİSİR A. E., TOHUMCUOĞLU M.
Acta Oncologica Turcica, vol.52, no.3, pp.372-378, 2019 (Peer-Reviewed Journal)
- XXXIV. **Chromosomal aberrations in multiple myeloma: clinical outcome and response to bortezomib**
AÇIKALIN A., BAĞIR KILIÇ E., PAYDAŞ S., ALSANCAK P., ERGİN M.
CUKUROVA MEDICAL JOURNAL, vol.44, no.2, pp.395-401, 2019 (ESCI)
- XXXV. **Effect of neoadjuvant chemotherapy on estrogen receptor, progesterone receptor, Cerb-B-2, vascular endothelial growth factor and Ki-67 in patients with locally advanced breast cancer**
SARITAŞ A. G., YALAV O., Kecec Y., SAKMAN G., BAĞIR KILIÇ E., ZORLUDEMİR S., ERGİN M., Eray T. C., Kara T. O., PAYDAŞ S.
CUKUROVA MEDICAL JOURNAL, vol.44, no.1, pp.226-231, 2019 (ESCI)
- XXXVI. **Malignant Mixed Müllerian Tumor of the Fallopian Tube: Rare Case**
KHATİP G., SOYSAL C., KÜÇÜKGÖZ GÜLEÇ Ü., GÜZEL A. B., VARDAR M. A., KILIÇ BAĞIR E., PAYDAŞ S.
Turkiye Klinikleri Journal of Gynecology and Obstetrics, vol.26, no.2, pp.55-57, 2018 (Scopus)
- XXXVII. **Acute promyelocytic leukemia after anthracycline containing chemotherapy for breast cancer: Case report and review of the literature**
MİRİLİ C., PAYDAŞ S., OĞUL A., GÖKÇAY S.
Journal of Oncological Sciences, vol.4, no.1, pp.62-64, 2018 (Peer-Reviewed Journal)
- XXXVIII. **Dynamic changes in PD-1 and PD-L1 expressions in cases with Hodgkin Lymphoma**
PAYDAŞ S., KILIÇ BAĞIR E., ERGİN M.
Clinical Research and Trials, vol.4, no.1, pp.1-5, 2018 (Peer-Reviewed Journal)
- XXXIX. **Hepatit C virüsü ve lenfoma ilişkisi: epidemiyoloji, patogenez, klinik özellikler ve tedavi**
PAYDAŞ S.
LLM Dergi, vol.2, no.1, pp.1-8, 2018 (Peer-Reviewed Journal)
- XL. **Pleural involvement in plasma cell neoplasm**
Bahceci A., PAYDAŞ S., BAĞIR KILIÇ E., Uguz A.
CUKUROVA MEDICAL JOURNAL, vol.43, no.2, pp.498-499, 2018 (ESCI)
- XLI. **G-CSF related hemophagocytosis in a case with lymphoma**
PAYDAŞ S., YETİŞİR E., MİRİLİ C., İSMAYİLOV E., BÜYÜKSİMŞEK M., OĞUL A., KILIÇ BAĞIR E., ERGİN M.
Clinical Research and Trials, vol.4, no.1, pp.1-2, 2018 (Peer-Reviewed Journal)
- XLII. **Acetabular Metastasis as Initial Presentation of Endometrial Cancer**
KHATİP G., CÖMERT E., KÜÇÜKGÖZ GÜLEÇ Ü., GÜZEL A. B., VARDAR M. A., KILIÇ BAĞIR E., PAYDAŞ S.
Turkiye Klinikleri Journal of Case Reports, vol.26, no.1, pp.27-29, 2018 (Peer-Reviewed Journal)
- XLIII. **Lymphocytic thyroiditis simulating thyroid cancer biochemically, radiologically and pathologically**
IŞIK u., GÖKÇAY S., ŞİMŞEK M., PAYDAŞ S., BÜYÜKDERELİ G., UĞUZ A. H.
Journal of Oncological Sciences, vol.4, pp.114-115, 2018 (Peer-Reviewed Journal)

- XLIV. **Pulmonary MALT lymphoma with underlying interstitial lung disease: A case report and review of the literature**
mirili c., PAYDAŞ S., oğul a., gökçay s., BÜYÜKŞİMŞEK M., YETİŞİR e., HANTA İ., ERGİN M., KILIÇ BAĞIR E., GÜNEY İ. B.
Journal of Oncological Sciences, vol.4, pp.56-59, 2018 (Peer-Reviewed Journal)
- XLV. **Super Scan Caused by Parathyroid Carcinoma Observed Both in¹⁸F-FDG PET/CT Scan and Tc-99m MDP Bone Scintigraphy.**
Güney İ. B., PAYDAŞ S., BALLI H. T.
Molecular imaging and radionuclide therapy, vol.26, pp.116-119, 2017 (ESCI)
- XLVI. **THE EVALUATION OF HOPELESSNESS AND PERCEIVED SOCIAL SUPPORT LEVEL IN PATIENTS WITH LUNG CANCER**
BOZDOĞAN S., ÖZTUNÇ G., YEŞİL DEMİRCİ P., İNEL MANAV A., PAYDAŞ S.
LIFE: International Journal of Health and Life-Sciences, vol.3, no.2, pp.88-105, 2017 (Peer-Reviewed Journal)
- XLVII. **THE EVALUATION OF HOPELESSNESS AND PERCEIVED SOCIAL SUPPORT LEVEL IN PATIENTS WITH LUNG CANCER**
BOZDOĞAN S., ÖZTUNÇ G., YEŞİL DEMİRCİ P., İNEL MANAV A., PAYDAŞ S.
LIFE: International Journal of Health and Life-Sciences, vol.3, no.2, pp.88-105, 2017 (Peer-Reviewed Journal)
- XLVIII. **THE EVALUATION OF HOPELESSNESS AND PERCEIVED SOCIAL SUPPORT LEVEL IN PATIENTS WITH LUNG CANCER**
BOZDOĞAN S., ÖZTUNÇ G., YEŞİL DEMİRCİ P., İNEL MANAV A., PAYDAŞ S.
LIFE: International Journal of Health and Life-Sciences, vol.3, no.2, pp.88-105, 2017 (Peer-Reviewed Journal)
- XLIX. **Gemcitabine-vinorelbine-prednisolone combination in cases with lymphoma: retrospective analysis**
PAYDAŞ S., KILIÇ BAĞIR E., ERGİN M.
Hematology Medical Oncology, vol.2, no.6, pp.2-5, 2017 (Peer-Reviewed Journal)
- L. **Acetabular Metstasis as Initial Presentation of Endometrial Cancer**
khatib g., CÖMERT E., KÜÇÜKGÖZ GÜLEÇ Ü., GÜZEL A. B., VARDAR M. A., BAĞIR e., PAYDAŞ S.
türkiye klinikleri j case rep, vol.26, no.1, pp.27-9, 2016 (Peer-Reviewed Journal)
- LI. **Primitive uterine neuroectodermal tumours: Two case reports**
Eskiyoruk I., KÜÇÜKGÖZ GÜLEÇ Ü., PAYDAŞ S., GÜZEL A. B., VARDAR M. A., BAĞIR KILIÇ E.
TURKISH JOURNAL OF OBSTETRICS AND GYNECOLOGY, vol.12, no.3, pp.185-187, 2015 (ESCI)
- LII. **Retrospective Analysis of 119 Osteosarcomas in a Single Centre Experience**
GÜNALDI M., DUMAN B. B., Ercolak V., Afsar C. U., PAYDAŞ S., ERKİSİ M., KARA İ. O., ŞAHİN B., GÖNLÜŞEN G.
JOURNAL OF CLINICAL AND ANALYTICAL MEDICINE, vol.6, pp.117-120, 2015 (ESCI)
- LIII. **Using Pazopanib and Radiotherapy to Treat Metastatic Renal Cell Carcinoma with Acrometastases**
USUL AFŞAR Ç., PAYDAŞ S.
International Journal of Medical and Pharmaceutical Case Reports, 2015 (Peer-Reviewed Journal)
- LIV. **ANTİ-CD20 ANTİKOR-RİTUKSİMAB VE İNFEKSİYON İLİŞKİSİ: BİR OLGU NEDENİYLE**
KURTARAN B., PAYDAŞ S., ULU A., YAVUZ S., İNAL A. S.
ANKEM Dergisi, vol.22, no.3, pp.156-159, 2008 (Peer-Reviewed Journal)
- LV. **Anti CD20 antikor rituksimab ve infeksiyon ilişkisi bir olgu nedeniyle**
KURTARAN B., CANDEVİR A., PAYDAŞ S., İNAL A. S., YAVUZ S.
ANKEM DERGİSİ, vol.22, no.3, pp.156-159, 2008 (Peer-Reviewed Journal)
- LVI. **Dramatic Improvement of Pulmonary Mucormycosis After Surgery in a Case Without Immunodeficiency**
POYRAZOĞLU H. H., PAYDAŞ S., UĞUZ A. H., ERKEN E., Yıldırım F., PAYDAŞ S., Kurt C., Ulus T.
INFECTIOUS DISEASES IN CLINICAL PRACTICE, vol.14, no.6, pp.403-405, 2006 (Scopus)
- LVII. **Bıçakçı, Ş., Aslan K., Bozdemir H., Paydaş S., ve Sarıca Y., ?Kronik Lenfositik Lösemi ve Santral Sinir Sistemi Tutulumu,?**
BIÇAKCI Ş., BOZDEMİR H., ASLAN K., PAYDAŞ S., SARICA Y.
TÜRK NÖROLOJİ DERGİSİ, vol.11, pp.411-414, 2005 (ESCI)
- LVIII. **Mide ve Kolorektal Kanserli Hastalarda Serum CA 72-4 ve CEA Değerlerinin Karşılaştırılması**
Kibar M., Sargın Ö., Paydaş S.

ÇUKUROVA ÜNİVERSİTESİ EĞİTİM FAKÜLTESİ DERGİSİ, vol.18, pp.251-259, 1993 (ESCI)

- LIX. **Concentrations of Trace Elements In 190 Patients With Various Malignancies.**
KEKEÇ M. Y., PAYDAŞ S., SÖNMEZ H., YAVUZ A., BAŞLAMIŞLI İ. F., YÜREĞİR G., KALKAN E., KALKAN E.
Anca Oncologica Turcica, vol.26, pp.9-14, 1993 (Peer-Reviewed Journal)
- LX. **İnterferon ve İnteraperitoneal Ufulanması**
KEKEÇ M. Y., PAYDAŞ S., ALTACA G.
Çukurova Üniversitesi Tıp Fakültesi Arşiv Dergisi, vol.2, pp.215-222, 1993 (Peer-Reviewed Journal)

Books & Book Chapters

- I. **Lymphocytosis: Causes, Pathogenesis and Approach for Patients with Lymphocytosis**
PAYDAŞ S., BAYRAM E.
in: Advances in Health and Disease, Duncan Lowell T., Editor, Nova medicine and health, New York, pp.193-212, 2022
- II. **monoclonal antibody treatments in multiple myeloma**
PAYDAŞ S.
in: advances in medicine and biology, Leon V. Berhardt, Editor, Nova medicine and health, New York, pp.187-210, 2020

Refereed Congress / Symposium Publications in Proceedings

- I. **736 Molecular classification and clinical significance in recurrent endometrial adenocarcinomas**
KÜÇÜKGÖZ GÜLEÇ Ü., PAYDAŞ S., KILIÇ BAĞIR E., AKBAL E., KÜÇÜKBİNGÖZ E., KHATİB G., GÜZEL A. B., VARDAR M. A.
International Journal of Gynecologic Cancer, 10 March 2024
- II. **ORTA-YÜKSEK RİSKLİ EMETOJENİK KEMOTERAPİ ALAN HASTALARDA FOSEPREPİTANT KULLANIMI:RETROSPEKTİF ANKET ÇALIŞMASI**
MİRİLİ C., KUMAŞ G., KURT Z., ALTINKAYA M., PAYDAŞ S.
9. Türk Tıbbi Onkoloji Kongresi, Girne, Cyprus (Kktc), 18 May 2022
- III. **İNDOLENT NON-HODGKİN LENFOMA HASTALARINDA EZH-2 İFADESİNİN PROGNOZ ÜZERİNDE ETKİSİ**
ŞENER M., KILIÇ BAĞIR E., DİNÇYÜREK H. D., SEYDAOĞLU G., PAYDAŞ S., GÜRKAN E.
46. Ulusal Hematoloji Kongresi/sanal kongre, Turkey, 28 - 31 October 2020, pp.90-91
- IV. **Clinical significance of c-MYC/EZH-2 expression and Merlin loss**
Arslan A. M., Paydas S., Gumurdulu D., Bagir E., Mirili C.
32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, ELECTR NETWORK, 24 - 25 October 2020, vol.138
- V. **Ribociclib for the treatment of hormone receptor-positive refractory advanced breast cancer: Managed access programme in Turkey**
Demirci U., GÖKMEN E., Eralp Y., Gunduz S., SEZGİN GÖKSU S., KORKMAZ T., Kostek O., Turhal S., PAYDAŞ S., Topcu S., et al.
San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 10 - 14 December 2019, vol.80
- VI. **Correlation of PET-CT and Bone Marrow Biopsy Results to Evaluate Bone Marrow Infiltration in HL Case Series**
YETİŞİR A. E., BÜYÜKŞİMŞEK M., TOHUMCUOĞLU M., PAYDAŞ S.
3. Ulusal İmmünoterapi ve Onkoloji Kongresi, Turkey, 30 October - 03 November 2019
- VII. **Clinical Significance of PRAME and PDL-1 Expression in Colon Cancer**
OĞUL A., PAYDAŞ S., DORAN F., EREN ATEŞ K., TOHUMCUOĞLU M., BÜYÜKŞİMŞEK M., YETİŞİR A. E., MİRİLİ C.
3. Ulusal İmmünoterapi ve Onkoloji Kongresi, Turkey, 30 October - 03 November 2019

- VIII. **A CLINICOPATHOLOGIC CHARACTERISTICS AND PROGNOSIS COMPARISON BETWEEN UTERINE CARCINOSARCOMAS AND UTERINE HIGH GRADE ENDOMETRIAL CARCINOMAS**
KÜÇÜKGÖZ GÜLEÇ Ü., PAYDAŞ S., GÜZEL A. B., KILIÇ BAĞIR E., KHATİB G., VARDAR M. A.
ESGO 2019 congress, 02 January 2020 - 05 November 2019
- IX. **Long-term Results of Brentuximab Vedotin in Relapsed and Refractory Hodgkin Lymphoma: Multi-center Real-life Experience**
FERHANOĞLU A. B., ÖZBALAK M. M., Salihoğlu A., SOYSAL T., Karadogan İ., PAYDAŞ S., Özdemir E., Yıldız B., KARADURMUŞ N., KAYNAR L., et al.
6th Aegean Hematology Oncology Symposium, 3 - 06 October 2019
- X. **Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable = Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey**
BEKSAÇ M., CENGİZ SEVAL G., PAYDAŞ S., TUĞLULAR A. T., ARSLAN Ö., GÖKER A. H., KAYNAR L., ALTUNTAŞ F., ATALAY F., ÜSKÜDAR TEKE H., et al.
17th International Myeloma Workshop, 12 - 15 September 2019
- XI. **LORLATINIB EXPERIENCE IN A CASE WITH NONSMALL CELL LUNG CANCER (NSCLC): HIGH EFFICACY BUT UNEXPECTED HIGH TOXICITY**
BÜYÜKŞİMŞEK M., PAYDAŞ S., YETİŞİR A. E., MİRİLİ C., OĞUL A., BAŞDOĞAN S.
23. Ulusal Kanser Kongresi, Turkey, 17 - 21 April 2019
- XII. **AGRESİF LENFOMADA DA-R-EPOCH TEDAVİ SONUÇLARIMIZ**
YETİŞİR A. E., PAYDAŞ S., BÜYÜKŞİMŞEK M., TOHUMCUOĞLU M.
23. ULUSAL KANSER KONGRESİ, Turkey, 17 - 21 April 2019
- XIII. **NHL OLGULARINDA TANI ANINDA PET-CT, KEMİK İLİĞİ İNFİLTRASYONUNU SAPTAMADA KEMİK İLİĞİ BİYOPSİSİNİN YERİNİ ALABİLİR Mİ?**
Kolsuz İ., Büyüksimşek M., Yetişir A. E., Paydaş S., Güney İ. B.
23. Ulusal Kanser Kongresi, Antalya, Turkey, 17 - 21 April 2019
- XIV. **Real life data from Turkey regarding the impact of first-line sunitinib and pazopanib in metastatic renal cell cancer.**
Isik U., Kostek O., Demiray G., Dirican A., Simsek M., Buyuksimsek M., Ucar G., Gunaydin U. M., Sakalar T., Aliyev A., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2019, vol.37
- XV. **Posttransplant lymphoproliferative disease (PTLPD)-Central nervous system (CNS) involvement in a case with liver transplantation: Case report and review of the literature**
KAKCI M., PAYDAŞ S., ASARKAYA E., ZORLUDEMİR S., acikalin a., bagir e., KURAN S.
7th International Congress on Leukemia Lymphoma Myeloma, 03 May 2019
- XVI. **NHL OLGULARINDA TANI ANINDA PET-CT, KEMİKİLİĞİ İNFİLTRASYONUNU SAPTAMADA KEMİK İLİĞİBİYOPSİSİNİN YERİNİ ALABİLİR Mİ?**
KOLSUZ İ., BÜYÜKŞİMŞEK M., Yetişir A. E., PAYDAŞ S., GÜNEY İ. B.
Ulusal Kanser Kongresi, Antalya, Turkey, 17 - 21 April 2019
- XVII. **Meme Kanserinde Neoadjuvan Kemoterapiye Yanıtın Öngörülmesinde İnflamatuvar Belirteçlerin Önemi**
BÜYÜKŞİMŞEK M., SÜMBÜL H. E., PAYDAŞ S.
2. Ulusal İmmunoterapi ve Onkoloji Kongresi, Turkey, 31 October - 04 November 2018
- XVIII. **NİVOLUMAB: 3. YIL ERKEN ERİŞİM PROGRAMI VERİLERİ**
MİRİLİ C., PAYDAŞ S., GÜNEY İ. B.
VIII. Ulusal Akciğer Kanseri Kongresi, BODRUM, Turkey, 4 - 07 October 2018
- XIX. **Myeloma böbreği: 8 olguda klinikopatolojik değerlendirme**
ALTUN DİNCELİR E., GÖNLÜŞEN G., PAYDAŞ S., KAYA B., ERDOĞAN K. E., PAYDAŞ S.
28. Ulusal Patoloji Kongresi, Turkey, 27 - 30 October 2018
- XX. **Crizotinib efficacy in ALK-positive advanced stage non-small cell lung cancer patients: a real-world**

experience from Turkey.

KILIÇKAP S., Öztürk A., KARADURMUŞ N., KORKMAZ T., YUMUK P. F., ÇİÇİN İ., PAYDAŞ S., ÇILBİR E., Sakalar T., UYSAL M., et al.

IASLC 19th World Conference On Lung Cancer, Canada, 23 - 26 September 2018, vol.13, pp.1020

- XXI. **PODOCYTURIA IN MULTIPLE MYELOMA PATIENTS HAS A TENDENCY TO INCREASE WITH TREATMENT**
KUZU T., PAYDAŞ S., GÜRKAN E., PAYDAŞ S., UĞUZ A. H.
23 rd CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION, Stockholm, Sweden, 14 - 17 June 2018, pp.216
- XXII. **Merkel cell carcinoma in Turkey: A multicentric study.**
yıldız f., BÜYÜKŞİMŞEK M., sakalar t., AYDIN Ö., TURNA Z. H., babacan n., arslan ç., ÖZDEMİR N., ÜRÜN Y., UYSAL M., et al.
2018 ASCO Annual Meeting, 1 - 05 June 2018
- XXIII. **EGFR, MUC-1 and PD-L1 expressions in cases with triple negative breast cancer (TNBC)**
MİRİLİ C., PAYDAŞ S., BAĞIR KILIÇ E., SEYDAOĞLU G., OĞUL A., BÜYÜKŞİMŞEK M., YETİŞİR A. E., TOHUMCUOĞLU M.
ASCO 2018, Chicago, United States Of America, 1 - 05 June 2018
- XXIV. **Son dönem böbrek yetmezliği ve Sistinozis:41 yaşında göz muayenesi ile tanı alabilen bir olgu sunumu.**
DEMİR İ., Şeker-Yılmaz B., KILAVUZ S., KOR D., BULUT F. D., ERDEM E., ÖNENLİ MUNGAN H. N., PAYDAŞ S.
VI. Uluslararası Katılımlı Lizozomal Hastalıklar Kongresi, Turkey, 11 - 15 April 2018
- XXV. **KEMOTERAPİ İLİŞKİLİ PELLAGRA**
OĞUL A., PAYDAŞ S., MİRİLİ C., BÜYÜKŞİMŞEK M., yetişir a. e., TOHUMCUOĞLU M., karaalioğlu b.
7. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2018
- XXVI. **EDİNSEL İMMÜN YETMEZLİKLİ BİR OLGUDA KAPOSİ SARKOMUNUN EŞLİK ETTİĞİ TAFRO SENDROMU**
TOHUMCUOĞLU M., PAYDAŞ S., OĞUL A., BÜYÜKŞİMŞEK M., yetişir a. e., KURTARAN B., ERGİN M., MİRİLİ C., karaalioğlu b.
7. Türk Tıbbi Onkoloji Konresi, Antalya, Turkey, 21 - 25 March 2018
- XXVII. **KÜÇÜK HÜCRELİ AKCİĞER KANSERİNDE (KHAK) NÖTROFİL LENFOSİT ORANI (NLO) İLE PET-CT'DE SAPTANAN METABOLİK PARAMETRELERİNİN (PET-CT MP) PROGNOZİK ÖNEMİ VE NLO İLE PET-CT MP İLİŞKİSİ**
MİRİLİ C., PAYDAŞ S., GÜNEY İ. B., SEYDAOĞLU G., KAPUKAYA T. K., OĞUL A., GÖKÇAY S.
7. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2018
- XXVIII. **EDİNSEL İMMÜN YETMEZLİKLİ BİR OLGUDA KAPOSİ SARKOMUNUN EŞLİK ETTİĞİ TAFRO SENDROMU**
TOHUMCUOĞLU M., PAYDAŞ S., OĞUL A., BÜYÜKŞİMŞEK M., YETİŞİR A. E., KURTARAN B., ERGİN M., MİRİLİ C., KARAALIOĞLU B.
7. Türk Tıbbi Onkoloji Kongresi, Turkey, 21 - 25 March 2018
- XXIX. **AKCİĞER ADENOKARSİNOMUNDA C-MET AMPLİFİKASYONU VE KRİZOTİNİB TEDAVİSİ OLGU SUNUMU**
YETİŞİR A. E., PAYDAŞ S., BÜYÜKŞİMŞEK M., OĞUL A., TOHUMCUOĞLU M.
7. Türk Tıbbi Onkoloji Kongresi, Turkey, 21 - 25 March 2018
- XXX. **KEMOTERAPİ İLİŞKİLİ PELLAGRA**
OĞUL A., PAYDAŞ S., MİRİLİ C., BÜYÜKŞİMŞEK M., YETİŞİR A. E., TOHUMCUOĞLU M., KARAALIOĞLU B.
7. Türk Tıbbi Onkoloji Kongresi, Turkey, 21 - 25 March 2018
- XXXI. **NIVOLUMAB ERKEN ERIŞİM PROGRAMI: UZUN DÖNEM TAKIPVERİLERİ**
Mirili C., Paydaş S., Güney İ. B., Oğul A., Gökçay S., Büyükşimşek M., Yetişir E., Tohumcuoğlu M., Karaalioğlu B.
7. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2018
- XXXII. **G-CSF RELATED HEMOPHAGOCYTOSIS IN A CASE WITH LYMPHOMA**
KARAALIOĞLU B., PAYDAŞ S., YETİŞİR E., MİRİLİ C., ISMAYİLOV E., BÜYÜKŞİMŞEK M., OĞUL A., KILIÇ BAĞIR E., ERGİN M.
7. Türk Tıbbi Onkoloji Kongresi, Turkey, 21 - 25 March 2018
- XXXIII. **Renal Primitif Nöroektodermal Tümör Olgu Sunumu**
YETİŞİR A. E., PAYDAŞ S., BÜYÜKŞİMŞEK M., OĞUL A.
Ulusal İmmünoterapi ve Onkoloji Kongresi, Turkey, 25 - 29 October 2017

- XXXIV. **MİKROBİYOTA, SAĞLIK VE HASTALIK**
PAYDAŞ S.
ICOHE, 7 - 09 December 2017
- XXXV. **NÜKS/REFRAKTER HODGKİN LENFOMA VAKALARINDA BRENTUXİMAB VEDOTİN'İN UZUN DÖNEM SONUÇLARI: ÇOK MERKEZLİ TÜRKİYE DENEYİMİ**
FERHANOĞLU A. B., salihoglu a., ÖZBALAK M., SOYSAL T., KARADOĞAN İ., PAYDAŞ S., ÖZDEMİR E., YILDIZ B., KARADURMUŞ N., KAYNAR L., et al.
43. ULUSAL HEMATOLOJİ KONGRESİ, Turkey, 1 - 04 November 2017
- XXXVI. **Programmed Death-1 (PD-1), Programmed Death Ligand 1 (PD-L1) Expression in Type 2 Endometrial Cancer.**
KÜÇÜKGÖZ GÜLEÇ Ü., KILIÇ BAĞIR E., PAYDAŞ S., SEYDAOĞLU G., GÜMÜRDÜLÜ D., GÜZEL A. B., VARDAR M. A.
20'th European Society of Gynecologic Oncology (ESGO) Congress, 4 - 07 November 2017
- XXXVII. **Programmed Death-1 (PD-1), Programmed Death-Ligand 1 (PD-L1) Expression in Uterine Carcinosarcomas.**
KÜÇÜKGÖZ GÜLEÇ Ü., KILIÇ BAĞIR E., PAYDAŞ S., SEYDAOĞLU G., GÜMÜRDÜLÜ D., GÜZEL A. B., VARDAR M. A.
20'th European Society of Gynecologic Oncology (ESGO) Congress 2017, Vienna, Austria., 4 - 07 November 2017
- XXXVIII. **Programmed Death-1 (PD-1), Programmed Death-Ligand 1 (PD-L1) Expression in Uterine Grade 3 Endometrioid Adenocarcinoma.**
KÜÇÜKGÖZ GÜLEÇ Ü., KILIÇ BAĞIR E., PAYDAŞ S., SEYDAOĞLU G., GÜMÜRDÜLÜ D., GÜZEL A. B., VARDAR M. A.
20'th European Society of Gynecologic Oncology (ESGO) Congress 2017, Vienna, Austria., 3 - 07 November 2017
- XXXIX. **Paratiroid karsinomlu, hiperkalsemik hastada perkutan alkol enjeksiyonu seçeneği**
OĞUL A., PAYDAŞ S., yetişir a. e., BÜYÜKŞİMŞEK M., MİRİLİ C.
Ulusal İmmünoterapi ve Onkoloji Kongresi, Antalya, Turkey, 25 - 29 October 2017
- XL. **Prephase tedavinin yüksek tümör yükü olan lenfomalı hastalarda tümör lizis sendromunu önlemede etkinliği.**
OĞUL A., PAYDAŞ S., yetişir a. e., MİRİLİ C., BÜYÜKŞİMŞEK M., GÖKÇAY S.
Ulusal İmmünoterapi ve Onkoloji Kongresi, Antalya, Turkey, 25 - 29 October 2017
- XLI. **Nüks veya Refrakter Hodgkin Lenfoma Hastalarında Nivolumab Kullanımı Türkiye Verileri**
FERHANOĞLU B., BEKÖZ H. S., KARADURMUŞ N., PAYDAŞ S., TÜRKER A., TOPTAŞ T., TUĞLULAR A. T., SÖNMEZ M., GÜLBAŞ Z., TEKGÜNDÜZ E., et al.
43. Ulusal Hematoloji Kongresi, Antalya, Turkey, 1 - 04 November 2017
- XLII. **Sarkomlarda PD-1 ve PD-L1 ekspresyonunun klinik ve prognostik önemi**
PAYDAŞ S., KILIÇ BAĞIR E., DEVECİ M. A., GÖNLÜŞEN G.
27. Ulusal Türk Ortopedi ve Travmatoloji Kongresi, Antalya, Turkey, 25 - 29 October 2017, vol.51, pp.122
- XLIII. **MASTEKTOMİ OPERASYONU GEÇİRMİŞ MEME KANSERLİ KADINLARDA AĞRININ DEĞERLENDİRİLMESİ**
ÖZTUNÇ G., YEŞİL DEMİRCİ P., TAŞCI S., PAYDAŞ S.
19. Ulusal İç Hastalıkları Kongresi, Antalya, Turkey, 11 - 15 October 2017, pp.325-326
- XLIV. **Mastektomi Operasyonu Geçirmiş Meme Kanseri Kadınlarında Ağrının Değerlendirilmesi**
ÖZTUNÇ G., YEŞİL DEMİRCİ P., TAŞCI S., PAYDAŞ S.
19. Ulusal İç Hastalıkları Kongresi, Turkey, 11 - 15 October 2017
- XLV. **Vitamin D gene polymorphism in multiple myeloma, chronic lymphocytic leukemia and chronic myeloid leukemia**
tombal a., ay M. E., Erdal M. E., Doğru G., Söylemez M., GÜRKAN E., PAYDAŞ S.
9th international conference on leukemia and hematologic malignancy, 5 - 06 October 2017
- XLVI. **Vitamin D gene polymorphism in multiple myeloma, chronic lymphocytic leukemia and chronic myeloid leukemia**
TOMBAK A., AY M. E., ERDAL M. E., DOĞRU ÖZDEMİR G., SÖYLEMEZ F., GÜRKAN E., PAYDAŞ S.
9th International Conference on Leukemia and Hematologic Oncology, London, Canada, 5 - 06 October 2017, vol.5
- XLVII. **Meta-analysis Of The Effect Of Rituximab In The Treatment Of Primary Central Nervous System Lymphoma**

YAVUZ S., YILDIRIM M., YAZICI G., kaya v., PAYDAŞ S.

ESMO, 8 - 12 September 2017

- XLVIII. **PD-1 and PD-L1 expression in thymic lesions**
KILIÇ BAĞIR E., AÇIKALIN A., AVCI A., GÜMÜRDÜLÜ D., PAYDAŞ S.
29th european congress of pathology, Amsterdam, Netherlands, 2 September - 06 December 2017, vol.471, pp.264
- XLIX. **Türkiye'den Çok Merkezli Erken Erişim Program Sonuçları: Daha Önce Yoğun Tedavi Almış Relaps/Refrakter Multipl Miyelom Hastalarında Daratumumabın Etkililik ve Güvenliliği**
BEKSAÇ M., GOKER H., TURGUT M., AYDIN Y., BESİSİK S., Cagiran S., Tuğlular T., Vural F., Yagci M., ALACACIOĞLU İ., et al.
Türk Hematoloji Derneği, Turkey, 17 - 20 August 2017
- L. **The Evaluation of Hopelessness and Perceived Social Support Level in Patients with Lung Cancer**
BOZDOĞAN S., ÖZTUNÇ G., YEŞİL DEMİRCİ P., İNEL MANAV A., PAYDAŞ S.
18th International Conference on Nursing & Midwifery (ICNM), Roma, Italy, 10 - 11 June 2017, pp.26
- LI. **Effectiveness of bendamustine in relapse or refractory lymphoma cases: A report from Turkey-The Turkish Oncology Group (TOG) study.**
Karadurmus N., Paydas S., Ocal R., Yildiz B., Nayir E., Dogan M., Sumbul A. T., Surmeli Z., Barista I., Ferhanoglu B., et al.
53rd Annual Clinical Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 2 - 07 June 2017, vol.35
- LII. **RAI Tedavisi Sonrası Gelişen Eozinofilik Myeloid Neoplazi ve Lenfoblastik Lenfoma Birlikteliği**
BÜYÜKŞİMŞEK M., YETİŞİR A. E., OĞUL A., GÖKÇAY S., MİRİLİ C., PAYDAŞ S.
22. ULUSAL KANSER KONGRESİ, Turkey, 19 - 23 April 2017
- LIII. **Real World Experience: Nivolumab Expanded Access Program in Turkey**
MİRİLİ C., PAYDAŞ S., GÖKÇAY S., OĞUL A., BÜYÜKŞİMŞEK M., YETİŞİR A. E.
22. ULUSAL KANSER KONGRESİ, Turkey, 19 - 23 April 2017
- LIV. **RAI TEDAVİSİ SONRASI GELİŞEN EOZİNOFİLİKMYELOİD NEOPLAZİ VE LENFOBLASTİK LENFOMA BİRLİKTELİĞİ**
BÜYÜKŞİMŞEK M., yetişir a. e., OĞUL A., GÖKÇAY S., MİRİLİ C., PAYDAŞ S.
22. ULUSAL KANSER KONGRESİ, Antalya, Turkey, 19 - 23 April 2017
- LV. **Endometrium Kanserli Olgularda Preoperatif Monosit Sayısı Nötrofil Lenfosit Oranı Ortalama Trombosit Hacmi Ortalama Trombosit Sayısının Trombosit Sayısına Oranı Trombosit Lenfosit Oranının Prognostik Önemi**
TEMUR İ., KÜÇÜKGÖZ GÜLEÇ Ü., PAYDAŞ S., KHATİB G., VARDAR M. A., GÜZEL A. B.
15. Ulusal Jinekolojik Onkoloji Kongresi, Turkey, 30 November - 04 December 2016
- LVI. **Asingle Institution Radical Surgery Results in Stage IB2 IIA2 Bulky Cervical Cancer**
KHATİB G., KÜÇÜKGÖZ GÜLEÇ Ü., GÜZEL A. B., UYGUR B., VARDAR M. A., GÜMÜRDÜLÜ D., PAYDAŞ S.
15. Ulusal Jinekolojik Onkoloji Kongresi, Turkey, 30 November - 04 December 2016
- LVII. **Timik orjinli lezyonlarda PD1 ve PD L1 ekspresyonu**
KILIÇ BAĞIR E., AÇIKALIN A., AVCI A., GÜMÜRDÜLÜ D., PAYDAŞ S.
26. Ulusal Patoloji Kongresi, Antalya, Turkey, 2 - 06 November 2016
- LVIII. **Castleman hastalığına eşlik eden pulmoner hyalinize granülom nadir bir olgu sunumu**
AÇIKALIN A., GÜMÜRDÜLÜ D., ERGİN M., KILIÇ BAĞIR E., AVCI A., ÖZYILMAZ SARAÇ E., PAYDAŞ S.
26. ulusal patoloji kongresi, Antalya, Turkey, 2 - 06 November 2016
- LIX. **Hodgkin lenfomada PD 1 ve PD L1 ekspresyonlarının tanı ve relaps durumunda değişimi İmmunoterapi ve dinamik süreç**
PAYDAŞ S., KILIÇ BAĞIR E., ERGİN M.
42. Ulusal Hematoloji Kongresi, Turkey, 19 - 23 October 2016
- LX. **T hücreli lenfomada yenilikler klinisyen gözüyle**
PAYDAŞ S.
Klinisyen Patolog ortak Lenfoma kursu, Turkey, 18 October 2016
- LXI. **pulmonary hyalinizing granuloma with castlemans disease a rare case report**

- AÇIKALIN A., GÜMÜRDÜLÜ D., ERGİN M., KILIÇ BAĞIR E., AVCI A., ÖZYILMAZ SARAÇ E., PAYDAŞ S.
XXXI international congress of the iap and 28th congress of ESP, köln, Germany, 25 - 29 September 2016
- LXII. **Human Herper Virus 8 related Kaposi sarcoma of the ureter after renal transplantation**
ZORLUDEMİR S., ERDOĞAN Ş., PAYDAŞ S.
XXXI International Congress of the International Academy of Pathology and 28th Congress of the European Society of Pathology, 25 - 29 September 2016
- LXIII. **Pulmonary hyalinizing granuloma with Castleman s Disease A rare case report**
AÇIKALIN A., GÜMÜRDÜLÜ D., ERGİN M., KILIÇ BAĞIR E., AVCI A., ÖZYILMAZ SARAÇ E., PAYDAŞ S.
XXXI International Congress of the International Academy of Pathology and 28th Congress of the European Society of Pathology, 25 - 29 September 2016
- LXIV. **Evaluation of Castleman disease A series of 50 cases**
KILIÇ BAĞIR E., AÇIKALIN A., PAYDAŞ S., ERGİN M.
XXXI International Congress of the IAP and 28th Congress of the ESP, Köln, Germany, 25 - 29 September 2016
- LXV. **Pulmonary hyalinizing granuloma with castleman s disease a rare case report**
AÇIKALIN A., GÜMÜRDÜLÜ D., ERGİN M., KILIÇ BAĞIR E., AVCI A., ÖZYILMAZ SARAÇ E., PAYDAŞ S.
XXXI International Congress of the IAP and 28th Congress of the ESP, köln, Germany, 25 - 29 September 2016
- LXVI. **clinical outcomes of the sarcomas in head and neck**
SÜRMEİOĞLU Ö., PAYDAŞ S., TUNCER Ü., ATEŞ K., ÖZDEMİR S., TARKAN Ö., BAYRAM İ., DAĞKIRAN M., UĞUZ A. H.
ECHNO 2016, 7 - 10 September 2016
- LXVII. **CLINICAL AND PATHOLOGIC RESULTS OF DENOSUMAB TREATMENT FOR GIANT CELL TUMORS OF BONE PROSPECTIVE STUDY ON 14 CASES**
DEVECİ M. A., PAYDAŞ S., GÖNLÜŞEN G., ÖZKAN C., BİÇER Ö. S., TEKİN M.
37th SICOT ORTHOPAEDICS WORLD CONGRESS 2016, 8 - 10 September 2016, pp.52
- LXVIII. **CLINICAL OUTCOMES OF THE SARCOMAS IN HEAD AND NECK**
SÜRMEİOĞLU Ö., PAYDAŞ S., TUNCER Ü., ATEŞ K., KÜPELİ S., ÖZDEMİR S., TARKAN Ö., BAYRAM İ., DAĞKIRAN M., UĞUZ A. H.
7th European Conference on Head and Neck Oncology, 7 - 10 September 2016
- LXIX. **CLINICAL OUTCOMES OF THE SARCOMAS IN HEAD AND NECK**
SÜRMEİOĞLU Ö., PAYDAŞ S., TUNCER Ü., ERDOĞAN K. E., KÜPELİ S., ÖZDEMİR S., TARKAN Ö., BAYRAM İ., DAĞKIRAN M., UĞUZ A. H.
7th European Conference on Head and Neck Oncology (ECHNO), 7 - 10 September 2016
- LXX. **Does Preoperative To Lymphocyte or platelet to lymphocyte ratios have a role in predicting borderline ovarian tumors**
KHATIB G., VARDAR M. A., GÜZEL A. B., KÜÇÜKGÖZ GÜLEÇ Ü., GÜMÜRDÜLÜ D., PAYDAŞ S.
ESGO PREVENTION GYNAECOLOGICAL MALGNANCIES, 8 - 10 September 2016, vol.26, pp.32
- LXXI. **The value of preoperative neutrophile to lymphocyte or platelet to lymphocyte ratios in predicting borderline ovarian tumors**
KHATIB G., VARDAR M. A., GÜZEL A. B., KÜÇÜKGÖZ GÜLEÇ Ü., GÜMÜRDÜLÜ D., PAYDAŞ S.
PREVENTION IN GYNECOLOGICAL CANCER, 8 - 10 September 2016
- LXXII. **Gemcitabine, Vinorelbine and prednisolone (GVP) rituximab combination in relaps refractory lymphoma cases retrospective analysis**
PAYDAŞ S., KILIÇ BAĞIR E., ERGİN M.
21st Congress of the European-Hematology-Association, kopenhag, Denmark, 9 - 12 June 2016
- LXXIII. **Changes in PD-1 and PD-L1 Expression in Cases with Hodgkin Lymphoma after Chemotherapy**
PAYDAŞ S., BAGIR E., ERGİN M., SEYDAOĞLU G.
57th Annual Meeting of the American-Society-of-Hematology, Florida, United States Of America, 5 - 08 December 2015, vol.126
- LXXIV. **Kemiğin Dev Hücreli Tümöründe Denosumab Gerçek mi Efsane mi**
DEVECİ M. A., PAYDAŞ S., GÖNLÜŞEN G., ÖZKAN C., BİÇER Ö. S., TEKİN M., TAN İ.
25. Ulusal Türk Ortopedi ve Travmatoloji Kongresi, Turkey, 27 October - 01 November 2015, vol.49, pp.40
- LXXV. **Carcinosarcoma of the Uterus A Single Institution Retrospective Analysis of the Management and**

Outcome

KÜÇÜKGÖZ GÜLEÇ Ü., PAYDAŞ S., GÜZEL A. B., GÜMÜRDÜLÜ D., GHANİM K., VARDAR M. A.

19th International Meeting of the European Society of Gynaecological Oncology (ESGO 2015), 24 - 27 October 2015

LXXVI. **Clinicopathological Features and Prognostic Factors of Ovarian Sex Cord Stromal Tumors**

KOÇAK B., KÜÇÜKGÖZ GÜLEÇ Ü., GHANİM K., GÜZEL A. B., GÜMÜRDÜLÜ D., PAYDAŞ S., VARDAR M. A.

19th International Meeting of the European Society of Gynaecological Oncology (ESGO 2015), 24 - 27 October 2015

LXXVII. **Castleman hastalığı**

KILIÇ BAĞIR E., AÇIKALIN A., ERGİN M., PAYDAŞ S.

25. ulusal patoloji kongresi, Bursa, Turkey, 14 - 17 October 2015

LXXVIII. **Metastatik breast carcinoma to intracranial microcystic meningioma case report and review of the literature**

ZORLUDEMİR S., PAYDAŞ S., ERGİN M., TORUN G., ERMAN T.

27th European congress of pathology, 5 - 09 September 2015

LXXIX. **The effect of platinum and docetaxel based chemoradiotherapy on survival in locally advanced unresectable non-small cell lung cancer patients.**

AFSAR C. U., GUNALDI M., KARACA F., Kara I. O., Sahin B., DUMAN B. B., ERKISI M., Paydas S.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33

LXXX. **The survival rate at 5 years in Turkish metastatic melanoma patients treated with ipilimumab: Final analysis of MIPI-TURK**

Sevinc A., Turna H., Ozdogan M., Buyukberber S., Mandel N. M., Demir G., Gokmen E., Paydas S., Akbulut H., Celik I.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33

LXXXI. **Clinical and pathological results of denosumab in the treatment of giant cell tumor of the bone**

DEVECİ M. A., PAYDAŞ S., GÖNLÜŞEN G., ÖZKAN C., BİÇER Ö. S., TEKİN M., TAN İ.

28th Annual meeting of the European Musculo-Skeletal Oncology Society, Atina, Greece, 29 April - 01 May 2015, pp.68-69

LXXXII. **Tuberoskleroz ve malign melanom birlikteliği**

MERAL g., PAYDAŞ S., USUL AFŞAR Ç., ERÇOLAK V., BOZKURT DUMAN b., DORAN F.

4. Tıbbi Onkoloji Kongresi, Turkey, 21 - 25 April 2015

LXXXIII. **Multisentrik Castleman hastalıklı olguda F 18 FDG PET BT nin tanısai değeri ve hasta yönetimine katkısı**

TÜMKAYA E., BÜYÜKDERELİ G., PAYDAŞ S., KILIÇ BAĞIR E.

XXVII. Ulusal Nükleer Tıp Kongresi, Turkey, 1 - 03 January 2015, vol.1, pp.38

LXXXIV. **Uterusun pirimitif nöroektodermal tümörü: 2 olgu sunumu**

ESKİYÖRÜK İ., KÜÇÜKGÖZ GÜLEÇ Ü., PAYDAŞ S., KILIÇ BAĞIR E., GÜMÜRDÜLÜ D., GÜZEL A. B., VARDAR M. A.

14. Ulusal jinekolojik onkoloji kongresi, Antalya, Turkey, 19 - 23 November 2014

LXXXV. **Boyunda Yaygın Metastaz ile Başvuran Epiteloid Sarkoma Benzeri Hemanjioendotelyoma**

ÖZDEMİR S., SÜRME LİOĞLU Ö., PAYDAŞ S., UĞUZ A. H.

36. Ulusal Kulak Burun Boğaz ve Baş Boyun Cerrahisi Kongresi, Turkey, 27 - 30 October 2014

LXXXVI. **The evaluation of endometrial thickness and bone mineral density based on CYP2D6 polymorphisms in Turkish breast cancer patients receiving tamoxifen treatment.**

GUNALDI M., ERKISI M., AFSAR C. U., ERCOLAK V., Paydas S., Kara I. O., Sahin B., Gulec U., Secilmis A.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32

LXXXVII. **Programmed death-1 (PD-1) and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma.**

Paydas S., Bagir E., Ergin M., Duman B. B., Ercolak V.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32

- LXXXVIII. **Kemiğin Dev Hücreli Tümörünün Tedavisinde Denosumab Kullanımının Sonuçları**
DEVECİ M. A., PAYDAŞ S., GÖNLÜŞEN G., BİÇER Ö. S., TEKİN M., TAN İ.
23. Ulusal Türk Ortopedi ve Travmatoloji Kongresi, Turkey, 29 October - 03 November 2013, vol.47, pp.50
- LXXXIX. **Multipl Myeloma Tanılı Otolog Transplantasyon Sonrası Total Vücut Işınlaması Olmaksızın Gelişen Ciddi Hipotiroidizm Olgusu**
BOZKURT DUMAN B., PAYDAŞ S., EVRAN M.
7. Ulusal Kemik İliği Transplantasyonu ve Kök Hücre Tedavileri Kongresi, Turkey, 8 - 12 March 2012
- XC. **The Prognostic Significance of Prame (preferentially Expressed Antigen of Melanoma) Expression in Breast Cancer**
DALCI K., RENCÜZOĞULLARI A., YALAV O., ERAY İ. C., KEKEÇ M. Y., PAYDAŞ S.
The 48th Congress of the European Society for Surgical Research, İstanbul, Turkey, 29 May - 01 June 2013
- XCI. **The Prognostic Significance of PRAME Preferentially Expressed Antigen Of Melenoma Expression in Breast Cancer**
DALCI K., RENCÜZOĞULLARI A., YALAV O., ERAY İ. C., KEKEÇ M. Y., PAYDAŞ S.
The 48th Congress of the European Society for Surgical Research, İstanbul, Turkey, 29 May - 01 June 2013
- XCII. **Multicentric ipilimumab experience in Turkish patients with metastatic melanoma: MIPI-TURK at 30 months of follow-up.**
Sevinc A., Turna H., Ozdogan M., Buyukberber S., Demir G., Gokmen E., Mandel N. M., Paydas S., Akbulut H., Celik I.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- XCIII. **MicroRNA profiles (including 370 miRNAs) in lymphomas.**
Paydas S., Acikalın A., Ergin M., Celik H., Yavuz B., Tanriverdi K.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- XCIV. **Nonalcoholic fatty liver disease after adjuvant therapy in nonmetastatic breast cancer.**
Duman B. B., Gunaldi M., Tasdogan B. E., Afsar C. U., Paydas S., Gumurdulu Y.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- XCV. **Çukurova Üniversitesi Tıp Fakültesi nde Tanı Konulmuş Pankreas Kanseri Hastalarımızın Retrospektif Olarak Değerlendirilmesi ve Derin Ven Trombozu İle Metastaz Yeri Ve Ortalama Trombosit Hacmi Arasındaki İlişkinin İncelenmesi**
USUL AFŞAR Ç., KUM p., ŞAHİN B., BOZKURT DUMAN b., GÜNALDI m., ERÇOLAK V., PAYDAŞ S., KARA İ. O., KÖKSAL ERKİŞİ M.
20. Ulusal Kanser Kongresi, Turkey, 19 - 23 April 2013
- XCVI. **The comparison of up-front autologous peripheral stem cell transplantation in first remission and long-lasting intensive chemotherapy protocols in highly aggressive non-Hodgkin's lymphomas: Results of a retrospective analysis.**
Ozturk M., Ozaydin S., Oyan B., Ozbalak M., Arpacı F., Paydas S., Ataergin S., Ferhanoglu B., Kocak N., Gurkan E., et al.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30
- XCVII. **Multicentric ipilimumab experience in Turkish patients with metastatic melanoma: MIPI-TURK.**
Sevinc A., Turna H., Ozdogan M., Buyukberber S., Demir G., Gokmen E., Mandel N. M., Paydas S., Akbulut H., Celik I.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30
- XCVIII. **Metastatik renal hücreli karsinomda sitoredüktif nefrektominin sağkalım üzerine etkisi**
BERNA b. d., ŞAHİN B., KÖKSAL ERKİŞİ M., PAYDAŞ S., KARA İ. O., USUL AFŞAR Ç., MERAL g., ERÇOLAK V., KUM p.
4. Tıbbi Onkoloji Kongresi, Turkey, 21 - 25 March 2012
- XCIX. **Genç bir erkek hastada yumuşak doku malign myoepitelyoması**
USUL AFŞAR Ç., PAYDAŞ S., GÖNLÜŞEN G., GÖNLÜŞEN G., meral g., ERÇOLAK V., ERÇOLAK V., berna b. d.

4. Tıbbi Onkoloji Kongresi, Turkey, 21 - 25 March 2012
- C. **Trastuzumab ilişkili kardiyotoksisiteye epirubisin ve doxorubisin katkısının karşılaştırması**
MERAL g, BERNA b. d., ERÇOLAK V., USUL AFŞAR Ç., PAYDAŞ S., KARA İ. O., KÖKSAL ERKİŞİ M., ŞAHİN B.
4. Tıbbi Onkoloji Kongresi, Turkey, 21 - 25 March 2012
- CI. **Kapesitabin ilişkili ciddi hipertrigliseridemi 2 olgu sunumu**
BERNA b. d., PAYDAŞ S., MERAL g., USUL AFŞAR Ç., ERÇOLAK V., TETİKER B. T., MERVE ş. d., VEYSEL h.
4. Tıbbi Onkoloji Kongresi, Turkey, 21 - 25 March 2012
- CII. **Akciğer Sarkomatoid Karsinomunun bir alt tipi Pulmoner Blastom**
USUL AFŞAR Ç., PAYDAŞ S., GÜMÜRDÜLÜ D., GÜNALDI m., ERÇOLAK V.
4. Tıbbi Onkoloji Kongresi, Turkey, 21 - 25 March 2012
- CIII. **Meme kanserli bir vakada TTF 1 pozitifliği**
USUL AFŞAR Ç., PAYDAŞ S., GÜMÜRDÜLÜ D., MERAL g., ERÇOLAK V., AÇIKALIN A.
4. Tıbbi Onkoloji Kongresi, Turkey, 21 - 25 March 2012
- CIV. **Gemsitabin İlişki Dress Sendromu Bir olgu nedeniyle**
ERTUĞRUL b., PAYDAŞ S., ZORLUDEMİR S., ABDURRAHMAN d., AÇIKALIN A., USUL AFŞAR Ç., GÜNALDI m.,
ERÇOLAK V., ERÇOLAK V.
4. Tıbbi Onkoloji Kongresi, Turkey, 21 - 25 March 2012
- CV. **Hemofagositoz ile Seyreden Fulminant Hepatit A Enfeksiyonu**
KURTARAN B., KARAKOÇ E., PAYDAŞ S., İNAL A. S., CANDEVİR A., TAŞOVA Y., AKSU H. S. Z.
2. EKMUD Kongresi, Ankara, Turkey, 29 April - 03 May 2008
- CVI. **EBV and VEGF-A expression in non-hodgkin's lymphoma**
Paydas S., Ergin M., Erdogan S., Seydaoglu G., Yavuz S.
ESMO Educational Conference Lugano (ECLU), Lugano, Switzerland, 01 January 2007, vol.18, pp.179
- CVII. **Thrombospondin1 (TSP1) and survivin (S) expression in cases with non-Hodgkin's lymphoma (NHL)**
Paydas S., Ergin M., Erdogan S., Yavuz S., Sydaoglu G.
30th Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006,
vol.17, pp.202
- CVIII. **The considering of medical student about practitioner**
BOZDEMİR N., Akçalı Ç., Işık O., Çetinalp E., BURGUT H. R., Kasap H., Doğan A., ZORLUDEMİR S., PAYDAŞ S., KESKİN
E., et al.
14th WONCA World conference, 10 June - 14 October 1995, pp.162
- CIX. **Gastrointestinal Lenfomalı Olgularımız**
PAYDAŞ S., KEKEÇ M. Y., Seyrek E., ŞAHİN B., ZORLUDEMİR S.
10. Ulusal Kanser Kongresi, İstanbul, Turkey, 3 - 07 May 1993
- CX. **Peritoneal Karsinomatosisde Sistemik Tedavi ile Birlikte İntraperitoneal Kemoterapi**
KEKEÇ M. Y., AKINOĞLU A., PAYDAŞ S.
Ulusal Cerrahi kongresi, İstanbul, Turkey, 14 - 18 May 1992

Supported Projects

- PAYDAŞ S., ASARKAYA E., ERGİN M., Project Supported by Higher Education Institutions, Plazma Hücreli Neoplazilerde MYC ve EZH2 Ekspresyonunun Klinik ve Prognoz Üzerine Etkisi, 2019 - 2021
- PAYDAŞ S., TOHUMCUOĞLU M., YETİŞİR A. E., GÖNLÜŞEN G., Project Supported by Higher Education Institutions, Malign Mezenkimal Tümör Hastalarında CD73 ve PDL-1 Pozitifliğinin Tedaviye Yanıt ve Prognoz ile ilişkisi, 2019 - 2020
- PAYDAŞ S., ZORLUDEMİR S., ERGİN M., TOHUMCUOĞLU M., BÜYÜKŞİMŞEK M., Project Supported by Higher Education Institutions, EZH2 Ve MUC1 Genlerinin Neoadjuvan Tedavi Alan Meme Kanseri Hastalarında Tedaviye Yanıt Etkilerinin Belirlenmesi, 2018 - 2020
- PAYDAŞ S., PAYDAŞ S., BÜYÜKŞİMŞEK M., Project Supported by Higher Education Institutions, Kemoterapi uygulanan hastalarda standart sıvı tedavisinin BCM ile değerlendirilmesi, 2017 - 2020
- PAYDAŞ S., ERGİN M., AÇIKALIN A., Kakıcı M., Project Supported by Higher Education Institutions, Hodgkin lenfomada

mikroçevrenin biyolojisinin belirlenmesi, 2018 - 2019

TOHUMCUOĞLU M., DORAN F., ERDOĞAN K. E., PAYDAŞ S., OĞUL A., Project Supported by Higher Education Institutions, KOLOREKTAL KANSERLERDE PRAME, MUC1 VE PDL-1 EKSPRESYONUNUN ÖNEMİ, 2017 - 2019

PAYDAŞ S., Project Supported by Higher Education Institutions, Sweets syndrome A revisit for hematologists and oncologists, 2015 - 2019

PAYDAŞ S., BAĞIR KILIÇ E., ERGİN M., Project Supported by Higher Education Institutions, Foliküler lenfoma olgularında DUSP22 yeniden düzenlenmesinin klinik önemi, 2017 - 2018

MİRİLİ C., ERGİN M., PAYDAŞ S., BAĞIR KILIÇ E., Project Supported by Higher Education Institutions, TRİPLE NEGATİF MEME KANSERLERİNDE MUC1 EGFR VE PDL1 EKSPRESYONLARININ KLİNİK ÖNEMİ, 2017 - 2018

PAYDAŞ S., PAYDAŞ S., ARAS D., UĞUZ A. H., GÜRKAN E., KUZU T., Project Supported by Higher Education Institutions, Yeni Tanılı Multipl Myelom Hastalarında Gelişen Nefropatinin Podositüri ile İlişkisi ve Tedaviye Yanıtının Değerlendirilmesi, 2016 - 2018

BOZDOĞAN YEŞİLOT S., YEŞİL P., ÖZTUNÇ G., İNEL MANAV A., PAYDAŞ S., Project Supported by Higher Education Institutions, Akciğer Kanserli Hastaların Sosyal Destek Algıları ve Umutsuzluk Düzeylerinin Değerlendirilmesi, 2016 - 2017

PAYDAŞ S., BAĞIR KILIÇ E., DEVECİ M. A., GÖNLÜŞEN G., Project Supported by Higher Education Institutions, Kemik ve Yumuşak doku sarkomlarında PD-1 ve PD-L1 ekspresyonunun klinik önemi, 2015 - 2016

YÜCEBİLGİÇ G., PAYDAŞ S., Project Supported by Higher Education Institutions, Paraoxonase1 Gene Polymorphisms and Serum Paraoxonase Activity in Turkish NonHodgkin Lymphoma Patients, 2015 - 2016

ERGİN M., ALSANCAK P., PAYDAŞ S., KARA İ. O., Project Supported by Higher Education Institutions, R-CHOP VE CHOP KEMOTERAPİ REJİMİ ALAN DİFFÜZ BÜYÜK B HÜCRELİ LENFOMALI HASTALARDA SİTOGENETİK VE İMMÜNFENOTİPİK ÖZELLİKLERİN ARAŞTIRILMASI VE BU ÖZELLİKLERİN SAĞKALIM ÜZERİNE ETKİSİNİN BELİRLENMESİ, 2015 - 2016

PAYDAŞ S., Project Supported by Higher Education Institutions, Antineoplastik Kemoterapi Alan Hastalarda Serolojik ve Non-invaziv yöntemlerle Kardiyotoksitenin Prospektif Olarak Değerlendirilmesi, 2013 - 2015

PAYDAŞ S., Project Supported by Higher Education Institutions, Hodgkin Lenfomada Epstein Barr Virüs (EBV) Ekspresyonunun Prognostik önemi, 2013 - 2015

PAYDAŞ S., Project Supported by Higher Education Institutions, Hodgkin Lenfomada Programmed Death-1 (PD-1) Ekspresyonunun Prognostik önemi, 2013 - 2014

Metrics

Publication: 381

Citation (WoS): 4018

Citation (Scopus): 3440

H-Index (WoS): 32

H-Index (Scopus): 30

Congress and Symposium Activities

TTOD NET?ler ve primeri bilinmeyen kanserler kursu, Session Moderator, İstanbul, Turkey, 2014

TTOD NET?ler ve primeri bilinmeyen kanserler kursu, Invited Speaker, İstanbul, Turkey, 2014

10.TOG çalıştayı Hedef tedavilerde yan etkiler kursu, Invited Speaker, Antalya, Turkey, 2014

40. Türk Hematoloji kongresi, Invited Speaker, Antalya, Turkey, 2014

Awards

PAYDAŞ S., TÜRKİYE KANSERLE SAVAŞ VAKFI BİLİM ÖDÜLÜ, TÜRKİYE KANSERLE SAVAŞ VAKFI, October 2014

PAYDAŞ S., Hodgkin lenfomada EBV, PD-1 ve PD-L1'in klinik önemi, Türk Hematoloji Derneği Klinik laboratuvar ödülü. 40.

Türk Hematoloji kongresi, October 2014

PAYDAŞ S., 2013 Dr. Nejat F. Eczacıbaşı Tıp Ödülü, Eczacıbaşı, October 2013

PAYDAŞ S., Hodgkin lenfomada PRAME gen ekspresyonu ve klinik önemi, TÜRKİYE KANSERLE SAVAŞ VAKFI, April 2013

PAYDAŞ S., Metastatik malign melanomalı Türk hastalarda çok merkezli ipilimumab deneyimi MİPİ-TÜRK, Türk Tıbbi Onkoloji Derneği, March 2012

PAYDAŞ S., BAYINDIR HASTANESİ BAYINDIR TIP BİLİM ÖDÜLÜ, BAYINDIR HASTANESİ, November 2009

PAYDAŞ S., Hamzalı köyü İlköğretim Okulu bilgi işlem sınıfı oluşturulması nedeniyle MİLLİ EĞİTİM BAKANLIĞI TEŞEKKÜR BELGESİ, MİLLİ EĞİTİM BAKANLIĞI, March 2008

PAYDAŞ S., NOVARTIS 2007 ONKOLOJİ BİLİM ÖDÜLÜ, NOVARTIS, April 2007

PAYDAŞ S., TÜRK KANSER ARAŞTIRMA VE SAVAŞ KURUMU ONKOLOJİ ARAŞTIRMA BİRİNCİLİK ÖDÜLÜ, TÜRK KANSER ARAŞTIRMA VE SAVAŞ KURUMU, April 2003

PAYDAŞ S., ?Non-Hodgkin Lenfomalarda serum ve dokuda anti-HCV ve HCV-RNA: KLİNİK PATOLOJİK KORELASYON?? TÜRK HEMATOLOJİ DERNEĞİ-LENFOPROLİFERATİF HASTALIKLAR İKİNCİLİK ÖDÜLÜ, TÜRK HEMATOLOJİ DERNEĞİ, October 2002

PAYDAŞ S., ?Plazmositomlarda VEGF ekspresyonu?? isimli çalışma ile XIV. KANSER KONGRESİ JÜRİ SERBEST BİLDİRİ ÖDÜLÜ, Tıbbi onkoloji derneği, April 2001

PAYDAŞ S., XIX. Gevher Nesibe Tıp Günleri Hematoloji-Onkolojide Güncel yaklaşımlar ve tümör oluşturma yöntemleri Workshop'ta sözlü bildiri üçüncülük ödülü, Erciyes Üniversitesi Tıp fakültesi, March 1998

PAYDAŞ S., ?p53 protein expression in leukemias?? ÇUKUROVA ÜNİVERSİTESİ TIP FAKÜLTESİ 25. YIL BİLİM ÖDÜLÜ, ÇUKUROVA ÜNİVERSİTESİ TIP FAKÜLTESİ, May 1997

PAYDAŞ S., Lösemi ve lenfomalarda uluslar arası bilime katkı nedeniyle TÜBİTAK TEŞVİK ÖDÜLÜ, TÜBİTAK, October 1994

PAYDAŞ S., Lösemilerde glutathion ve p53 gen mutasyonları?? isimli çalışma ile PROF DR BEDİİ GORBON ÖDÜLÜ, TÜRKİYE KANSERLE SAVAŞ VAKFI, April 1993

Non Academic Experience

Çukurova Üniversitesi